

PROTEINBENCH: A HOLISTIC EVALUATION OF PROTEIN FOUNDATION MODELS

Anonymous authors

Paper under double-blind review

ABSTRACT

Recent years have witnessed a surge in the development of protein foundation models, significantly improving performance in protein prediction and generative tasks ranging from 3D structure prediction and protein design to conformational dynamics. However, the capabilities and limitations associated with these models remain poorly understood due to the absence of a unified evaluation framework. To fill this gap, we introduce ProteinBench, a holistic evaluation framework designed to enhance the transparency of protein foundation models. Our approach consists of three key components: (i) A taxonomic classification of tasks that broadly encompass the main challenges in the protein domain, based on the relationships between different protein modalities; (ii) A multi-metric evaluation approach that assesses performance across four key dimensions: quality, novelty, diversity, and robustness; and (iii) In-depth analyses from various user objectives, providing a holistic view of model performance. Our comprehensive evaluation of protein foundation models reveals several key findings that shed light on their current capabilities and limitations. To promote transparency and facilitate further research, we release the evaluation dataset, code, and a public leaderboard publicly for further analysis and a general modular toolkit. We intend for ProteinBench to be a living benchmark for establishing a standardized, in-depth evaluation framework for protein foundation models, driving their development and application while fostering collaboration within the field.

1 INTRODUCTION

Proteins are fundamental molecules playing pivotal roles in a vast array of biological processes, from enzymatic catalysis and signal transduction to structural support and immune response. Their functions are determined by their amino acid sequences, often mediated through folding into specific three-dimensional structures. Understanding the complex interplay between protein sequence, structure, and function is crucial for advancing science and engineering spanning pharmaceuticals, agriculture, specialty chemicals, and biofuels (Kuhlman & Bradley, 2019).

In recent years, there has been a surge in the development of protein foundation models¹ aimed at understanding fundamental biological processes by capturing the intricate mechanisms of proteins (Jumper et al., 2021; Abramson et al., 2024; Lin et al., 2023a; Watson et al., 2023b; Ingraham et al., 2023; Krishna et al., 2024; Shin et al., 2021; Madani et al., 2023; Alley et al., 2019; Wang et al., 2024b; Hayes et al., 2024; Hie et al., 2024). These models, leveraging advanced deep-learning and generative AI techniques, have demonstrated remarkable capabilities and marks a significant shift from traditional, task-specific approaches to more generalizable frameworks capable of learning complex patterns and relationships within vast protein datasets. For instance, AlphaFold3 (Abramson et al., 2024), which is based on diffusion models, has achieved unprecedented accuracy in full atom structure prediction for all biomolecules, while others like the ESM series (Rives et al., 2021; Hsu et al., 2022; Lin et al., 2023a; Verkuil et al., 2022; Hayes et al., 2024) and DPLM (Wang et al., 2024b) have shown impressive representation capability in protein language modeling benefiting diverse downstream tasks. Furthermore, these foundation models are not limited to single modalities. Multi-modal models that jointly consider sequence, structure, and function are emerging, offering a comprehensive understanding of protein behavior (Hayes et al., 2024; Liu et al., 2023). In addition

¹In this study, we broaden the definition of protein foundation models to include any generative models aimed at addressing foundational problems of protein sciences.

Table 1: Overview of ProteinBench, which summarizes the dimensions, metrics, and methods used in ProteinBench. We use *italics* for highlighting, a method that has not yet been evaluated in ProteinBench but will be assessed in the future. [Details regarding task selection, metric design principles, and implementation specifics are provided in the corresponding sections.](#)

| Tasks | Dimension | Metrics | Methods |
|--|-------------------|---|---|
| Protein Design | | | |
| Inverse Folding (Section B.1.1) | Sequence recovery | AAR | ProteinMPNN, ESMIF1, LM-Design, ESM3 <i>PiFold, CarbonDesign</i> |
| | Refoldability | scTM (AF2) | |
| | Stability | pLDDT (AF2) | |
| | Robustness | | |
| Backbone Design (Section B.1.2) | Quality | scTM, scRMSD (ProteinMPNN & ESMFold) | Rfdiffusion, Frameflow, Chroma, Framediff, Foldflow, Genie, <i>Proteus</i> <i>foldngdiff</i> |
| | Novelty | Max. TM score to PDB database (Foldseek) | |
| | Diversity | Pairwise TM, Max Cluster (Foldseek) | |
| Sequence Design (Section B.1.3) | Quality | pLDDT (AF2) | ProGen2, EvoDiff, DPLM, ESM3 |
| | Novelty | Max. TM to PDB database (Foldseek) | |
| | Diversity | Pairwise TM, Max Cluster (Foldseek) | |
| Struct-seq Co-design (Section B.1.4) | Quality | scTM, scRMSD (ESMFold) | ProteinGenerator, ProtPardelle, Multiflow, ESM3, <i>CarbonNovo</i> |
| | Novelty | Max. TM score to PDB database (Foldseek) | |
| | Diversity | Pairwise TM, Max Cluster (Foldseek) | |
| Motif Scaffolding (Section B.1.5) | Quality | Motif RMSD, Scaffold RMSD | FrameFlow, Rfdiffusion, TDS, EvoDiff, DPLM, ESM3 |
| | | | |
| Antibody Design (Section B.1.6) | Accuracy | AAR, RMSD, TM-score | HERN, MEAN, dyMEAN, DiffAb, AbDPO |
| | Functionality | Binding Energy (Rosetta) | |
| | Specificity | Seq Similarity, PHR | |
| | Rationality | CN-Score, Clashes, Seq Naturalness Total Energy (Rosetta), scRMSD (IgFold) | |
| Protein Conformation Prediction | | | |
| Single-state (folding) (Section B.2.1) | Accuracy | TM-score, RMSD, GDT, IDDT | AlphaFold2, OpenFold, ESMFold, <i>RoseTTAFold2, EigenFold</i> |
| | Quality | CA clash, Peptide bond break | |
| Multiple-state (Section B.2.2) | Accuracy | Ensemble TM-score/RMSD | EigenFold, MSA-subsampling, Str2Str, AlphaFlow/ESMFlow, <i>ConfDiff, Distributed graphormer</i> |
| | Diversity | Pairwise RMSD/TM-score | |
| | Quality | CA clash, Peptide bond break | |
| Distribution Prediction (Section B.2.3) | Accuracy | Flexibility accuracy, Distributional similarity, Ensemble observables | |
| | Diversity | Pairwise RMSD, RMSF | |
| | Quality | CA clash, Peptide bond break | |

tein design, some users may prioritize models that fit natural evolutionary distributions, while others may seek models capable of generating novel proteins outside the training set distribution. By analyzing model capabilities from these different objectives, ProteinBench provides insights that are beneficial for a wide range of practical applications.

(4) Leaderboard and code framework. To facilitate fair comparisons and support the development of new methods, we provide a unified experimental framework. This includes a public leaderboard and open-source code, enabling researchers to easily benchmark their models against existing ones and contribute to the ongoing advancement of the field.

By incorporating these four components, ProteinBench aims to establish a standardized, comprehensive, and user-centric evaluation framework for protein foundation models. This approach not only illuminates the current state-of-the-art but also guides future research directions and accelerates progress in the field of protein modeling and design.

2 PROTEINBENCH

In this section, we provide ProteinBench, a holistic evaluation framework for protein foundation models as shown in Table 1, with a particular focus on two key generative tasks: protein design and conformation prediction. These two areas are further divided into eight subtasks. [For each task, we focus on the following aspects: More details about the task definitions, evaluations, and discussions can be found in Appendix B.](#)

2.1 PROTEIN DESIGN

We evaluate protein foundation models on six design tasks using standardized metrics, enabling cross-task comparisons and assessment of different modeling approaches.

2.1.1 INVERSE FOLDING

Inverse folding is a fundamental task aiming to design amino acid sequences that can fold into predetermined structures. Evaluations were conducted on different datasets targeting two distinct objectives of structure-based sequence design: evolutionary distribution capturing and de novo protein design. [For more detailed information, please refer to Section B.1.1.](#) Evaluation results are presented in Table 2. Our analysis of native distribution fitness reveals that language model-based method LM-DESIGN (Zheng et al., 2023) achieve high sequence recovery rates for native protein structure-based sequence design. This suggests that these models effectively learn and replicate the intricate patterns of amino acid selection that have emerged through evolutionary processes. While

Table 2: Performance of structure-based sequence design models on inverse folding tasks. The reported results are the median of repetitive experiments. 'N/A' stands for not applicable. ESMIF1 and ESM3 use all native structures and sequences for model training, therefore, they not measured in the evolution distribution fitting objective.

| Objectives | Fitting Evolution Distribution | | De novo backbones based sequence design | | | | | | | | | |
|-------------|--------------------------------|----------------|---|------------------|-----------------|------------------|-----------------|------------------|-----------------|------------------|-----------------|------------------|
| | CASP | CAMEO | length 100 | | length 200 | | length 300 | | length 400 | | length 500 | |
| | AAR \uparrow | AAR \uparrow | scTM \uparrow | pLDDT \uparrow | scTM \uparrow | pLDDT \uparrow | scTM \uparrow | pLDDT \uparrow | scTM \uparrow | pLDDT \uparrow | scTM \uparrow | pLDDT \uparrow |
| ProteinMPNN | 0.450 | 0.468 | 0.962 | 94.14 | 0.945 | 89.34 | 0.962 | 90.28 | 0.875 | 83.76 | 0.568 | 67.09 |
| ESM-IF1 | N/A | N/A | 0.810 | 88.83 | 0.635 | 69.67 | 0.336 | 74.36 | 0.449 | 64.59 | 0.462 | 58.97 |
| LM-DESIGN | 0.516 | 0.570 | 0.834 | 78.45 | 0.373 | 58.41 | 0.481 | 69.86 | 0.565 | 59.87 | 0.397 | 56.35 |
| ESM3 | N/A | N/A | 0.942 | 86.60 | 0.486 | 60.69 | 0.632 | 70.78 | 0.564 | 62.63 | 0.452 | 59.37 |

its performance decreases when applied to de novo backbone-based sequence design. Conversely, ProteinMPNN (Dauparas et al., 2022a), a method specifically developed for de novo design and trained using coordinates perturbed with 0.2Å added noise, consistently demonstrates superior performance in de novo design tasks. However, ProteinMPNN’s performance shows a decline when evaluated on the objective of fitting to native evolution. [This finding suggests no single model currently excels across all inverse folding objectives. The choice of model should be carefully aligned with the intended applications.](#)

ESM-IF1 (Hsu et al., 2022), trained on AlphaFoldDB (Varadi et al., 2022) using GVP (Jing et al., 2020) and Transformer architectures with 0.1Å noise, showed suboptimal performance in de novo backbone sequence design. While the model excels at functional mutation prediction as demonstrated in ProteinGYM (Notin et al., 2024), these tasks were not included in our study. The recently released ESM3 (Hayes et al., 2024) performs similarly to ESM-IF1, with advantages at specific sequence lengths (100, 300, and 400 residues). PiFold (Gao et al., 2022) and CarbonDesign (Ren et al., 2024) are not currently included in ProteinBench.

2.1.2 STRUCTURE DESIGN

[Protein backbone design focuses on generating new protein folds to expand the repertoire of protein structures beyond those found in nature. Further details are provided in Section B.1.2.](#) Evaluation results are presented in Table 3 and Table 12. Based on the quality metrics of scTM-score and scRMSD, RFdiffusion (Watson et al., 2023b) demonstrates exceptional performance in backbone design for chain lengths ranging from 50 to 300 amino acids. FrameFlow (Yim et al., 2023) achieves the second-best performance in this range. However, we observe a significant performance decrease across all models for longer chains (500 amino acids), with scTM scores dropping by more than 20%. This decline suggests that developing methods for long-chain backbone design remains an important challenge for future research. [Proteus \(Wang et al., 2024a\) shows a superior design quality for long-chain backbones \(500 residues\).](#) However, we observed a significant decline in structure diversity for long chains. Novelty is an equally important metric, as it gauges a method’s capacity to explore new structural space beyond known protein folds. Under moderate quality constraints (scTM score >0.5), FoldFlow (Bose et al., 2023) and Genie (Lin & AlQuraishi, 2023) exhibit good performance in generating novel structures. When we increase the quality threshold (scTM score >0.8), Chroma (Ingraham et al., 2023) generally shows the best performance across chain lengths from 50 to 500 amino acids. For structural diversity, Chroma shows commendable performance across the tested chain lengths. It is important to note that we used the released FoldFlow model trained on a smaller training set with shorter sequences. This limitation may lead to an unfair comparison of the model architecture to other methods trained on the entire PDB database, particularly for longer chain lengths. [Foldingdiff \(Wu et al., 2024a\) is not featured in ProteinBench.](#)

2.1.3 SEQUENCE DESIGN

[Protein sequence design aims to generate amino acid sequences with desired properties. See Section B.1.3 for details.](#) In this section, we assess the performance of various protein sequence generative models. The evaluation metrics include AlphaFold2 (AF2) predicted pLDDT scores for structural plausibility (quality), maximum TM-score and maximum cluster values for structural diversity, and maximum TM-score to PDB structures for structural novelty. We choose representative methods of distinct modeling foundations for evaluation. Among the methods evaluated, ProGen2 (Nijkamp et al., 2023) is an autoregressive protein language model (AR-LM), while EvoDiff (Alamdari et al., 2023) is designed as an order-agnostic autoregressive diffusion model (OADM). DPLM (Wang et al., 2024b) and ESM3 (Hayes et al., 2024) share a probabilistic foundation as absorbing discrete diffusion models or generative masked language models. Notably, ESM3 is a multimodal model that

Table 3: Performance of backbone design models evaluated using various lengths ranging from 50 to 500. The reported results are the median of repetitive experiments. We highlight the **best** performance in bold and the second-best with the underline. For the novelty and diversity metrics, we only highlight results with the corresponding scTM score higher than 0.5. 'N/A' stands for not applicable.

| | length 50 | | | | | length 100 | | | | |
|-------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-----------------------|
| | Quality | | Novelty | | Diversity | Quality | | Novelty | | Diversity |
| | scTM \uparrow | scRMSD \downarrow | Max TM \downarrow | pairwise TM \downarrow | Max Clust. \uparrow | scTM \uparrow | scRMSD \downarrow | Max TM \downarrow | pairwise TM \downarrow | Max Clust. \uparrow |
| Native PDBs | 0.91 \pm 0.11 | 0.74 \pm 1.45 | N/A | 0.29 \pm 0.03 | 0.66 | 0.96 \pm 0.10 | 0.67 \pm 1.61 | N/A | 0.30 \pm 0.02 | 0.77 |
| RFdiffusion | 0.95\pm0.12 | 0.45\pm1.71 | 0.65 \pm 0.16 | 0.58 \pm 0.05 | 0.67 | 0.98\pm0.12 | 0.48\pm0.56 | 0.76 \pm 0.01 | 0.41 \pm 0.03 | 0.32 |
| FrameFlow | 0.91 \pm 0.09 | 0.58 \pm 0.51 | 0.75 \pm 0.01 | 0.68 \pm 0.10 | 0.39 | 0.94 \pm 0.08 | 0.70 \pm 0.70 | 0.72 \pm 0.01 | 0.55 \pm 0.08 | 0.49 |
| Chroma | 0.85 \pm 0.15 | 1.05 \pm 1.49 | 0.59 \pm 0.08 | 0.29 \pm 0.01 | 0.48 | 0.89 \pm 0.13 | 1.27 \pm 1.85 | 0.70 \pm 0.01 | 0.35 \pm 0.03 | 0.59 |
| FrameDiff(latest) | 0.85 \pm 0.13 | 1.00 \pm 1.27 | 0.67 \pm 0.01 | 0.35 \pm 0.02 | 0.64 | 0.90 \pm 0.08 | 1.23 \pm 1.02 | 0.71 \pm 0.08 | 0.52 \pm 0.05 | 0.11 |
| FoldFlow1(sfm) | 0.90 \pm 0.10 | 0.67 \pm 0.88 | 0.68 \pm 0.03 | 0.63 \pm 0.07 | 0.48 | 0.87 \pm 0.11 | 1.34 \pm 1.42 | 0.65 \pm 0.01 | 0.49 \pm 0.08 | 0.83 |
| FoldFlow1(base) | 0.79 \pm 0.14 | 1.19 \pm 1.27 | 0.66 \pm 0.02 | 0.53 \pm 0.08 | 0.76 | 0.81 \pm 0.15 | 1.70 \pm 1.95 | 0.62 \pm 0.01 | 0.48 \pm 0.07 | 0.83 |
| FoldFlow1(ot) | 0.83 \pm 0.16 | 1.10 \pm 1.53 | 0.65 \pm 0.02 | 0.53 \pm 0.08 | 0.77 | 0.83 \pm 0.15 | 1.60 \pm 1.95 | 0.64 \pm 0.01 | 0.48 \pm 0.06 | 0.81 |
| Genie | 0.57 \pm 0.15 | 3.12 \pm 2.07 | 0.57\pm0.03 | 0.32\pm0.02 | 0.90 | 0.69 \pm 0.17 | 3.38 \pm 3.04 | 0.59\pm0.01 | 0.31\pm0.02 | 0.96 |
| Proteus | - | - | - | - | - | 0.94 \pm 0.12 | 0.84 \pm 0.52 | 0.73 \pm 0.10 | - | 0.5 |

| | length 300 | | | | | length 500 | | | | |
|-------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-----------------------|
| | Quality | | Novelty | | Diversity | Quality | | Novelty | | Diversity |
| | scTM \uparrow | scRMSD \downarrow | Max TM \downarrow | pairwise TM \downarrow | Max Clust. \uparrow | scTM \uparrow | scRMSD \downarrow | Max TM \downarrow | pairwise TM \downarrow | Max Clust. \uparrow |
| Native PDBs | 0.97 \pm 0.10 | 0.82 \pm 2.67 | N/A | 0.28 \pm 0.02 | 0.77 | 0.97 \pm 0.17 | 1.07 \pm 5.96 | N/A | 0.29 \pm 0.03 | 0.8 |
| RFdiffusion | 0.96\pm0.15 | 1.03\pm3.14 | 0.64 \pm 0.01 | 0.36\pm0.03 | 0.65 | 0.79 \pm 0.19 | 5.60 \pm 5.66 | 0.62 \pm 0.004 | 0.33 \pm 0.02 | 0.89 |
| FrameFlow | 0.92 \pm 0.15 | 1.95 \pm 2.76 | 0.65 \pm 0.01 | 0.43 \pm 0.07 | 0.88 | 0.61 \pm 0.19 | 7.92 \pm 4.08 | 0.61 \pm 0.01 | 0.40 \pm 0.06 | 0.92 |
| Chroma | 0.87 \pm 0.13 | 2.47 \pm 3.63 | 0.66 \pm 0.01 | 0.36\pm0.04 | 0.67 | 0.72 \pm 0.18 | 6.71 \pm 5.76 | 0.60 \pm 0.01 | 0.29\pm0.01 | 0.99 |
| FrameDiff(latest) | 0.87 \pm 0.12 | 2.73 \pm 2.69 | 0.69 \pm 0.00 | 0.48 \pm 0.04 | 0.21 | 0.63 \pm 0.24 | 9.52 \pm 18.19 | 0.58\pm0.03 | 0.40 \pm 0.06 | 0.52 |
| FoldFlow1(sfm) | 0.45 \pm 0.11 | 9.04 \pm 2.52 | 0.54 \pm 0.01 | 0.39 \pm 0.04 | 1.00 | 0.37 \pm 0.06 | 13.04 \pm 1.71 | 0.53 \pm 0.01 | 0.37 \pm 0.03 | 1.00 |
| FoldFlow1(base) | 0.43 \pm 0.09 | 9.56 \pm 2.42 | 0.54 \pm 0.01 | 0.39 \pm 0.05 | 0.98 | 0.35 \pm 0.05 | 13.20 \pm 2.29 | 0.52 \pm 0.01 | 0.39 \pm 0.05 | 1.00 |
| FoldFlow1(ot) | 0.54 \pm 0.12 | 8.21 \pm 2.38 | 0.58\pm0.00 | 0.41 \pm 0.06 | 0.94 | 0.37 \pm 0.06 | 12.48 \pm 2.00 | 0.51 \pm 0.01 | 0.35 \pm 0.03 | 1.00 |
| Genie | 0.27 \pm 0.02 | 20.37 \pm 1.70 | 0.30 \pm 0.01 | 0.23 \pm 0.01 | 1.00 | 0.25 \pm 0.01 | 26.08 \pm 1.58 | 0.22 \pm 0.002 | 0.23 \pm 0.004 | 1.00 |
| Proteus | 0.94 \pm 0.06 | 1.46 \pm 1.08 | 0.78 \pm 0.05 | - | 0.34 | 0.90\pm0.13 | 2.76\pm3.57 | 0.72 \pm 0.02 | - | 0.34 |

Table 4: Performance of protein sequence generative models/language models on sequence generation tasks. The reported results are the average of repetitive experiments with the standard derivation. The pLDDT score is the output of AlphaFold2. Max TM is an abbreviation for Maximum TM-score to PDB database. 'N/A' stands for not applicable. We highlight the **best** performance in bold.

| | length 100 | | | | | length 200 | | | | |
|-----------------|---------------------------------|-----------------------------------|---------------------------------|-----------------------|---------------------------------|---------------------------------|----------------------------------|---------------------------------|-----------------------|---------------------------------|
| | Quality | | Diversity | | Novelty | Quality | | Diversity | | Novelty |
| | ppl \downarrow | pLDDT \uparrow | pairwise TM \downarrow | Max Clust. \uparrow | Max TM \downarrow | ppl \downarrow | pLDDT \uparrow | pairwise TM \downarrow | Max Clust. \uparrow | Max TM \downarrow |
| Native Seqs | | 68.46 \pm 16.50 | 0.55 \pm 0.19 | 0.75 | N/A | | 61.91 \pm 11.62 | 0.49 \pm 0.10 | 0.78 | N/A |
| Progen 2 (700M) | 8.28 \pm 3.87 | 64.00 \pm 21.26 | 0.42\pm0.10 | 0.94 | 0.64\pm0.08 | 5.68 \pm 3.64 | 69.91 \pm 9.23 | 0.40 \pm 0.13 | 0.91 | 0.69\pm0.05 |
| EvoDiff | 16.89 \pm 1.04 | 50.20 \pm 10.27 | 0.43 \pm 0.05 | 0.98 | 0.69 \pm 0.03 | 17.28 \pm 1.64 | 50.66 \pm 16.38 | 0.36 \pm 0.04 | 1.00 | 0.71 \pm 0.02 |
| DPLM (650M) | 6.21\pm3.10 | 85.38\pm14.20 | 0.50 \pm 0.20 | 0.80 | 0.74 \pm 0.10 | 4.61\pm2.63 | 93.54\pm3.73 | 0.54 \pm 0.24 | 0.70 | 0.91 \pm 0.004 |
| ESM3 (1.4B) | 14.79 \pm 2.90 | 54.26 \pm 15.35 | 0.45 \pm 0.15 | 0.90 | 0.68 \pm 0.07 | 12.96 \pm 2.38 | 58.45 \pm 9.40 | 0.35\pm0.07 | 1.00 | 0.80 \pm 0.01 |

| | length 300 | | | | | length 500 | | | | |
|-----------------|---------------------------------|----------------------------------|---------------------------------|-----------------------|---------------------------------|--------------------------------|-----------------------------------|---------------------------------|-----------------------|---------------------------------|
| | Quality | | Diversity | | Novelty | Quality | | Diversity | | Novelty |
| | ppl \downarrow | pLDDT \uparrow | pairwise TM \downarrow | Max Clust. \uparrow | Max TM \downarrow | ppl \downarrow | pLDDT \uparrow | pairwise TM \downarrow | Max Clust. \uparrow | Max TM \downarrow |
| Native Seqs | | 61.49 \pm 14.47 | 0.51 \pm 0.13 | 0.85 | N/A | | 62.95 \pm 12.60 | 0.51 \pm 0.11 | 0.78 | N/A |
| Progen 2 (700M) | 6.25 \pm 4.02 | 65.69 \pm 20.93 | 0.42 \pm 0.16 | 0.93 | 0.66\pm0.06 | 4.27 \pm 3.60 | 61.45 \pm 20.17 | 0.32 \pm 0.11 | 0.95 | 0.68 \pm 0.08 |
| EvoDiff | 17.13 \pm 2.00 | 45.14 \pm 9.95 | 0.31\pm0.03 | 1.00 | 0.68 \pm 0.02 | 16.51 \pm 3.82 | 43.14 \pm 5.16 | 0.31\pm0.03 | 1.00 | 0.69 \pm 0.02 |
| DPLM (650M) | 3.47\pm1.44 | 93.07\pm5.77 | 0.57 \pm 0.25 | 0.63 | 0.91 \pm 0.01 | 3.33\pm1.8 | 87.73\pm11.61 | 0.43 \pm 0.18 | 0.85 | 0.85 \pm 0.04 |
| ESM3 (1.4B) | 14.59 \pm 2.97 | 48.08 \pm 13.34 | 0.32 \pm 0.03 | 1.00 | 0.75 \pm 0.02 | 11.10 \pm 2.26 | 52.17 \pm 10.52 | 0.30 \pm 0.05 | 1.00 | 0.54\pm0.03 |

advances beyond other sequence-only methods by jointly learning protein sequences, structures and functions through tokenization. For each model and sequence length, we sample 50 sequences to evaluate their performance.

As shown in Table 4, DPLM consistently shows the highest quality scores, indicating superior accuracy in sequence generation. However, it has relatively lower diversity metrics, suggesting less variation in its generated sequences. EvoDiff, while demonstrating lower pLDDT scores, excels in diversity, particularly in producing highly diverse sequence clusters. Surprisingly, ESM3, a multi-modal protein LM, displays lower pLDDT in sequence generation, while maintaining competitive diversity, especially in generating novel sequences. ProGen2 strikes a balance between quality and diversity, offering moderate pLDDT scores and satisfactory diversity and novelty. This model is effective for generating sequences that are both diverse and close to known structures, depending on specific application needs. Regarding different chain lengths, all the models generally exhibit consistent trends in their performance metrics. As the chain length increases, there is a slight decline in the quality of sequences generated by some models, particularly for EvoDiff and ESM3. This indicates a challenge in maintaining high sequence quality as the chain length grows. Among them, DPLM demonstrates robust performance across all lengths, maintaining high pLDDT even for longer sequences. Overall, DPLM is good at highly structural protein sequence generation, while

Table 5: Performance of protein co-design models on structure-sequence co-generation tasks. The reported results are the average of repetitive experiments with the standard derivation. We highlight the best performance in bold and the second-best with the underline. *: We have tried our best to reproduce all models according to the instructions in their respective codebases, using publicly available model weights. However, some results may differ from those reported in the original studies. We welcome any feedback and corrections to help us make timely updates in the future.

| | length 100 | | | | length 200 | | | |
|------------------|---------------------------------|---------------------------------|-----------------------|---------------------|---------------------------------|---------------------------------|-----------------------|---------------------|
| | Quality | | Diversity | Novelty | Quality | | Diversity | Novelty |
| | scTM \uparrow | scRMSD \downarrow | Max Clust. \uparrow | Max TM \downarrow | scTM \uparrow | scRMSD \downarrow | Max Clust. \uparrow | Max TM \downarrow |
| Native PDBs | 0.91 \pm 0.11 | 2.98 \pm 3.49 | 0.75 | N/A | 0.88 \pm 0.09 | 3.24 \pm 3.77 | 0.77 | N/A |
| ProteinGenerator | 0.91 \pm 0.08 | 3.75 \pm 3.39 | 0.24 | 0.73 | 0.88 \pm 0.09 | 6.24 \pm 4.10 | 0.25 | 0.72 |
| ProtPardelle | 0.91 \pm 0.09 | 2.07 \pm 1.87 | 0.73 | 0.16 | 0.92 \pm 0.04 | 2.36 \pm 1.19 | 0.09 | 0.75 |
| Multiflow | 0.96\pm0.04 | 1.10\pm0.71 | 0.33 | 0.71 | 0.95\pm0.04 | <u>1.61\pm1.73</u> | 0.42 | <u>0.71</u> |
| CarbonNovo | 0.91 \pm 0.14 | 1.16 \pm 1.03 | 0.71 | 0.69 | 0.94 \pm 0.09 | 1.18\pm1.47 | 0.50 | <u>0.71</u> |
| ESM3* | 0.72 \pm 0.19 | 13.80 \pm 10.51 | 0.64 | <u>0.41</u> | 0.63 \pm 0.20 | 21.18 \pm 16.19 | 0.63 | 0.61 |
| | length 300 | | | | length 500 | | | |
| | Quality | | Diversity | Novelty | Quality | | Diversity | Novelty |
| | scTM \uparrow | scRMSD \downarrow | Max Clust. \uparrow | Max TM \downarrow | scTM \uparrow | scRMSD \downarrow | Max Clust. \uparrow | Max TM \downarrow |
| Native PDBs | 0.92 \pm 0.12 | 3.94 \pm 4.95 | 0.75 | N/A | 0.90 \pm 0.14 | 9.64 \pm 7.05 | 0.80 | N/A |
| ProteinGenerator | 0.81 \pm 0.14 | 9.26 \pm 4.13 | 0.22 | 0.71 | 0.41 \pm 0.19 | 33.91 \pm 15.10 | 0.18 | 0.73 |
| ProtPardelle | 0.94 \pm 0.02 | 2.07 \pm 0.73 | 0.05 | 0.73 | 0.41 \pm 0.10 | 41.10 \pm 8.85 | 0.14 | 0.65 |
| Multiflow | 0.96\pm0.06 | 2.14 \pm 3.24 | 0.58 | 0.71 | 0.83 \pm 0.15 | 8.48 \pm 7.02 | 0.67 | 0.68 |
| CarbonNovo | 0.95 \pm 0.08 | 1.33\pm1.59 | 0.31 | 0.74 | 0.85\pm0.15 | 4.07\pm4.14 | 0.67 | 0.68 |
| ESM3* | 0.59 \pm 0.21 | 25.5 \pm 20.68 | <u>0.52</u> | 0.73 | 0.54 \pm 0.20 | 33.70 \pm 21.08 | 0.37 | 0.77 |

EvoDiff and ESM3 are preferable for better diversity and novelty, with ProGen2 offering a balanced performance across metrics.

2.1.4 STRUCTURE AND SEQUENCE CO-DESIGN

Protein structure-sequence co-design represents a challenge in protein engineering that involves the simultaneous generation of both backbone structure and amino acid sequence. We evaluate the structural quality, novelty, and diversity similarly to backbone design. See Section B.1.4 for details. in Table 5. We inspect the performance of ProteinGenerator (Lisanza et al., 2023), ProtPardelle (Chu et al., 2024), Multiflow (Campbell et al.), CarbonNovo (Ren et al., 2024) and ESM3 (Hayes et al., 2024) for different lengths. The performance is assessed using metrics similar to those applied in backbone generation. Note that, however, the quality here is about structure-sequence compatibility measuring how well the designed sequence can fold into the corresponding designed structure, using scTM and scRMSD. The key difference is that co-design models are tasked with simultaneously generating both the sequence and structure, while backbone design models require an additional inverse folding model, such as ProteinMPNN, to design the sequence. Other metrics used for evaluation include diversity (max cluster) and novelty (max TM-score to PDB).

As shown in Table 5, ProteinGenerator, ProtPardelle, CarbonNovo, and Multiflow consistently show strong performance of structure-sequence compatibility when length less than 300, with high scTM scores (up to 0.96 \pm 0.06) and relatively low scRMSD values, indicating superior structural quality in generated sequences. ProtPardelle and ProteinGenerator particularly excel at shorter lengths while failing at long proteins. CarbonNovo and Multiflow maintain high performance even as sequence length increases, demonstrating their robustness with consistently high scTM scores and lower scRMSD values, which indicates their capability to generate high-quality structures. ESM3, on the other hand, shows suboptimal performance by its low scTM scores and very high scRMSD values, suggesting that it struggles with unconditional generation. Overall, these findings suggest that CarbonNovo and Multiflow are particularly robust and superior as a co-design protein generative model across all tested lengths.

2.1.5 MOTIF SCAFFOLDING

Motif scaffolding represents a specialized challenge in protein design that focuses on creating protein structures incorporating specific functional motifs or binding sites. See Section B.1.5 for more details. In this section, we evaluate the performance of various motif-scaffolding methods across different scaffolds used in Watson et al. (2023b) and Yim et al. (2024), focusing on their effectiveness in designing scaffold structures. The primary objective of this evaluation is to compare the efficacy of structure-based and sequence-based approaches in generating designable scaffolds. For purely

Table 6: Performance of antibody design methods on 55 antibody-antigen complexes from the RABD dataset. For methods that can generate multiple antibodies (marked with *), the standard deviations between different antibodies generated against the same antigen are also reported.

| | Accuracy | | | Functionality | | Specificity | |
|----------------|-------------------|-------------------|---------------------------------|-------------------------------------|---------------------------|-------------------------|--------------------|
| | AAR \uparrow | RMSD \downarrow | TM-score \uparrow | Binding Energy \downarrow | SeqSim-outer \downarrow | SeqSim-inner \uparrow | PHR \downarrow |
| RABD (natural) | 100.00% | 0.00 | 1.00 | -15.33 | 0.26 | N/A | 45.78% |
| HERN | 33.17% | 9.86 | 0.16 | 1242.77 | 0.41 | N/A | 39.83% |
| MEAN | 33.47% | 1.82 | 0.25 | 263.90 | 0.65 | N/A | <u>40.74%</u> |
| dyMEAN | 40.95% | 2.36* | 0.36 | 889.28 | 0.58 | N/A | 42.04% |
| *dyMEAN-FixFR | 40.05% \pm 1.06 | 2.37 \pm 0.03 | 0.35 \pm 0.01 | 612.75 \pm 56.03 | 0.60 | 0.96 | 43.75% \pm 2.24 |
| *DiffAb | 35.04% \pm 8.36 | 2.53 \pm 0.60 | 0.37\pm0.06 | 489.42 \pm 499.76 | 0.37 | 0.45 | 40.68% \pm 10.65 |
| *AbDPO | 31.29% \pm 7.29 | 2.79 \pm 3.01 | 0.35 \pm 0.06 | 116.06\pm186.06 | 0.38 | 0.60 | 69.69% \pm 8.49 |
| *AbDPO++ | 36.25% \pm 7.95 | 2.48 \pm 0.59 | 0.35 \pm 0.06 | 223.73 \pm 281.7 | 0.39 | 0.54 | 44.51% \pm 9.55 |

| | Rationality | | | | | |
|----------------|---------------------------------|---------------------------------|---------------------------------|-------------------|-------------------------------------|---------------------------------|
| | CN-score \uparrow | Clashes-inner \downarrow | Clashes-outer \downarrow | SeqNat \uparrow | Total Energy \downarrow | scRMSD \downarrow |
| RABD (natural) | 50.19 | 0.07 | 0.00 | -1.74 | -16.76 | 1.77 |
| HERN | 0.04 | 0.04 | 3.25 | -1.47 | 5408.74 | 9.89 |
| MEAN | 1.33 | 11.65 | 0.29 | -1.83 | 1077.32 | 2.77 |
| dyMEAN | 1.49 | 9.15 | 0.47 | -1.79 | 1642.65 | 2.11 |
| *dyMEAN-FixFR | 1.14 \pm 1.71 | 8.88 \pm 0.55 | 0.48 \pm 0.12 | -1.82 \pm 0.10 | 1239.29 \pm 113.84 | <u>2.48\pm0.24</u> |
| *DiffAb | <u>2.02\pm2.83</u> | <u>1.84\pm1.35</u> | 0.19 \pm 0.31 | -1.88 \pm 0.47 | 495.69 \pm 350.96 | 2.57 \pm 0.77 |
| *AbDPO | 1.33 \pm 2.31 | 4.14 \pm 1.84 | <u>0.10\pm0.24</u> | -1.99 \pm 0.34 | 270.12\pm217.45 | 2.79 \pm 3.25 |
| *AbDPO++ | 2.34\pm3.20 | 1.66\pm1.28 | 0.08\pm0.20 | -1.78 \pm 0.43 | 338.14 \pm 266.48 | 2.50 \pm 0.75 |

sequence-based methods, e.g., EvoDiff (Alamdari et al., 2023) and DPLM (Wang et al., 2024b), we use ESMFold to predict the structures of their designed motif-scaffold sequences.




Figure 2: Performance of motif-scaffolding of structure-based and sequence-based methods on the benchmark used in Watson et al. (2023b). Results of FrameFlow, RFDiffusion and TDS are quoted from Yim et al. (2024)³.

Figure 2 reveals a wide range of performance levels among the tested methods, each exhibiting distinct strengths and weaknesses depending on the specific scaffold context. Notably, structure-based methods such as RFDiffusion (Watson et al., 2023b), TDS (Wu et al., 2024b) and FrameFlow (Yim et al., 2024) consistently perform well across most scenarios, with RFDiffusion showing particular robustness in generating a high number of designable scaffolds. This suggests that structure-based methods are highly effective at capturing the intricate structural details necessary for successful scaffold design. In contrast, sequence-based methods like EvoDiff and DPLM display variable performance, excelling in certain scaffolds that are primarily governed by evolutionary constraints, but underperforming in others with more complex structural motifs. This variability may reflect their limitations in recognizing and adapting to specific structural features.

Interestingly, we find that ESM3 (Hayes et al., 2024), a recent multimodal language model that handles both sequence and structure, performs similarly to advanced structure-based models and even succeeds in cases where those models fail. This shows that multimodal models like ESM3 can process both types of information within a unified framework, making them useful for conditional design. However, ESM3 still doesn't outperform structure-based methods in most cases. Our results highlight that no single model is best for all scaffolds. Future research should focus on combining these methods to leverage their strengths for more effective protein design.

2.1.6 ANTIBODY DESIGN

Antibody designing aims to generate antibodies that specifically bind to target antigens (details refer to B.1.6 [Task Definition]). In this section, we selected five antigen-specific antibody design methods (HERN (Jin et al., 2022), MEAN (Kong et al., 2022), dyMEAN (Kong et al., 2023), DiffAb (Luo et al., 2022), AbDPO (Zhou et al., 2024)) and two of their variants (dyMEAN-FixFR and AbDPO++) to evaluate their performance in CDR-H3 generation towards the given antigens. All

³https://github.com/microsoft/protein-frame-flow/tree/main/motif_scaffolding

Table 7: Performance of protein folding on CAMEO2022. Results are reported as mean/median over 183 proteins. The **best** performance is highlighted in bold, and the second-best is underlined. EigenFold only predicts CA coordinates and PepBond break % is not available (shown in “N/A”).

| | Accuracy | | | | Quality | |
|--------------|---------------------|-------------------|--------------------|--------------------|---------------------------|--------------------------------|
| | TM-score \uparrow | RMSD \downarrow | GDT-TS \uparrow | IDDT \uparrow | CA clash (%) \downarrow | PepBond break (%) \downarrow |
| AlphaFold2 | 0.871/0.952 | 3.21/1.64 | 0.860/0.921 | 0.904/0.933 | 0.3/0.0 | 4.8/4.1 |
| OpenFold | 0.870/0.947 | 3.21/1.59 | 0.856/0.913 | 0.899/0.933 | 0.4/0.0 | 2.0/1.7 |
| RoseTTAFold2 | 0.859/0.941 | 3.52/1.75 | 0.845/0.903 | 0.892/0.926 | 0.3/0.0 | 5.5/4.0 |
| ESMFold | 0.847/0.929 | 3.98/2.10 | 0.826/0.881 | 0.870/0.907 | 0.3/0.0 | <u>4.7/3.4</u> |
| EigenFold | 0.743/0.823 | 7.65/3.73 | 0.703/0.781 | 0.737/0.810 | 8.0/4.6 | N/A |

methods were trained on the same dataset with the configurations reported in the corresponding papers and tested on a unified set of 55 test cases from the RAbD dataset (Adolf-Bryfogle et al., 2018) (further details of model implementation and data construction are provided in Appendix B.1.6 [Model Implementations]) The final results of the evaluation are shown in Table 6. For each evaluation metric, we highlighted the **best** performance in bold and the second-best with the underline, the detailed concept and implementation of each metric can be seen in Appendix B.1.6 [Evaluation Metrics].

In the **Accuracy** evaluation, dyMEAN, and MEAN achieved the best performance in terms of sequence and structure (highest **AAR** and lowest **RMSD**), while DiffAb performed best in **TM-score**.

In the **Functionality** evaluation, all methods produced antibodies with binding energies to the given antigens significantly higher than those of natural antibodies. AbDPO and AbDPO++ achieved the best performance among all the methods.

In the **Specificity** evaluation, we mainly observed the sequence similarity between antibodies against different antigens (**SeqSim-outer**) and the proportion of hydrophobic residues in the generated antibodies (**PHR**). The former metric indicates whether the method can design antibodies specific to a given antigen and DiffAb, AbDPO, and AbDPO++ achieved better performance, while the latter reflects the potential nonspecific binding due to high hydrophobicity and HERN performed best.

In the **Rationality** evaluation, we mainly observed: structural rationality, sequence rationality, and joint structural and sequence rationality. AbDPO++ performed best in structural rationality with fewer clashes and reasonable peptide bond length. HERN performed best in sequence rationality with the highest naturality. AbDPO and dyMEAN perform best in joint structural and sequence rationality from two perspectives. Details of the Specificity and Rationality evaluation refer to Appendix B.1.6 [Extended Explanations and Discussion on Model Performance].

In general, evaluating antibody design methods encompasses various aspects, and using only a few metrics will seriously mislead researchers’ understanding of model performance. No single method outperformed all others across the board, and all methods showed substantial gaps compared to natural antibodies. However, AbDPO++, by utilizing synthetic data and aligning with various properties, achieved one of the best performances in almost all metrics among all methods.

2.2 PROTEIN CONFORMATION PREDICTION

Protein conformation prediction infers the 3D *conformations* of proteins from their sequences, evaluating models based on their understanding of structure, dynamics, and ultimately functions. We begin by benchmarking common folding models, as they play a crucial role in the development of conformation prediction models. We then compare five recent studies that explore different strategies to extend folding to conformation prediction, focusing on *multiple-state* and *distribution prediction* tasks. A detailed discussion of task definition, evaluation, and discussion can be found in Section B.2.

2.2.1 PROTEIN FOLDING: SINGLE-STATE PREDICTION

Protein folding task predicts the 3D structure of a protein based on its sequence. This sequence-to-structure prediction is a critical measure of a model’s understanding of these two modalities. See Section B.2.1 for more details. As the results shown in Table 7, Multiple Sequence Alignment (MSA) based folding models (AlphaFold2, OpenFold, RoseTTAFold2) outperforms protein language model-based approaches (ESMFold, EigenFold). While the predicted structure quality is comparable among the all-atom resolution models, AlphaFold2 and its reproduction, OpenFold, achieve the best performance across all accuracy metrics, offering a strong foundation for conformation prediction.

Table 8: Performance of the multiple-state prediction on BPTI. *Accuracy* metrics (RMSDens, RMSD Cluster 3) are reported as the mean and standard deviations from 20 bootstrap samples, at different sample sizes. *Diversity* and *quality* are evaluated based on 1,000 conformations.

| | RMSDens (Å) ↓ | | | RMSD (Å) Cluster 3 ↓ | | | Diversity | | Quality |
|-----------------------------------|------------------|------------------|------------------|----------------------|------------------|------------------|---------------|-------------|------------------|
| | N=10 | N=100 | N=1000 | N=10 | N=100 | N=1000 | Pairwise RMSD | CA clash% ↓ | PepBond break% ↓ |
| EigenFold | 1.56±0.02 | 1.50±0.01 | 1.46±0.00 | 2.54±0.03 | 2.48±0.01 | 2.46±0.01 | 0.85 | 1.4 | N/A |
| MSA-depth32 | 1.66±0.03 | 1.54±0.04 | 1.41±0.02 | 2.43±0.06 | 2.19±0.16 | 1.85±0.05 | 2.14 | 0.6 | 10.6 |
| Str2Str-ODE ($T_{\max} = 0.15$) | 2.40±0.12 | 2.20±0.05 | 2.09±0.01 | 3.00±0.20 | 2.73±0.12 | 2.58±0.05 | 1.86 | 0.0 | 13.9 |
| ESMFlow-MD | 1.68±0.06 | 1.47±0.04 | 1.39±0.03 | 2.44±0.11 | 2.27±0.10 | 2.18±0.02 | 1.17 | 0.0 | 14.3 |
| ConfDiff-ESM-Force | 1.58±0.04 | 1.43±0.03 | 1.36±0.01 | <u>2.44±0.06</u> | 2.35±0.05 | 2.24±0.06 | 1.76 | 0.1 | 8.9 |

Table 9: Performance of multiple-state prediction on *apo-holo*. *apo/holo*-TM represents the maximum TM-score of the samples relative to the reference *apo/holo* structure. 20 conformations were sampled for each protein, and the results are reported as mean across 91 proteins.

| | Accuracy | | | Diversity | | Quality | |
|----------------------------------|------------------|-------------------|--------------|-------------|--------------|-------------------|--|
| | <i>apo</i> -TM ↑ | <i>holo</i> -TM ↑ | TMens ↑ | Pairwise TM | CA clash % ↓ | PepBond break % ↓ | |
| <i>apo</i> model | 1.000 | 0.790 | 0.895 | N/A | N/A | N/A | |
| EigenFold | 0.831 | 0.864 | 0.847 | 0.907 | 3.6 | N/A | |
| MSA-depth256 | 0.845 | 0.889 | 0.867 | 0.978 | 0.2 | 4.6 | |
| Str2Str-ODE ($T_{\max} = 0.3$) | 0.766 | 0.781 | 0.774 | 0.872 | 0.2 | 14.7 | |
| AlphaFlow-PDB | 0.855 | 0.891 | 0.873 | 0.924 | 0.3 | 6.6 | |
| ConfDiff-Open-PDB | <u>0.847</u> | 0.886 | <u>0.867</u> | 0.909 | 0.5 | <u>5.5</u> | |

2.2.2 MULTIPLE-STATE PREDICTION

Multiple-state prediction builds upon single-state prediction by aiming to accurately generate two or more distinct conformational states of a protein, which are typically associated with functional conformational changes. Further details can be found in B.2.2. Regarding evaluation, we first investigate the results on **BPTI** with the best model of each study highlighted in Table 8 and the complete evaluation in Table 13. The classifier-free guidance in ConfDiff (Wang et al., 2024c) achieved performance comparable to fine-tuning on MD conformation data and, when combined with force guidance, delivered the best overall accuracy (RMSDens). This suggests that incorporating structural exploration and physical constraints can enhance the sampling of high-accuracy conformations. However, structural exploration alone may be error-prone as Str2Str (Lu et al., 2024), the structure-only models, showed low accuracy even with small perturbations. Other strategies to enhance conformation sampling also showed improved performance: MSA subsampling (Del Alamo et al., 2022) with reduced MSA depth excelled at sampling Cluster 3, the most difficult state to capture, and ESMFlow (Jing et al., 2024) fine-tuned on the MD dataset showed improved diversity and accuracy compared to the PDB-trained base model. However, these approaches also experienced a decline in quality, with increased CA clashing or peptide bond breaking. Lastly, for most methods, increasing the sample depth (N) significantly improved expected accuracy, suggesting that a sufficient sample size is essential for thorough evaluation.

apo-holo is a more challenging dataset where models are required to predict both the unbound (*apo*) and bound (*holo*) conformations induced by ligand binding. As shown in Table 9 and Table 14, strategies to enhance conformation diversity did not improve the TMens score, and the best-performing models closely resemble folding models. In comparison, a baseline model that consistently predicts the perfect *apo* structure achieved a higher TMens score. These findings suggest that these models struggle to accurately sample *apo-holo* conformation changes, and higher accuracy may stem from using a stronger folding model.

In summary, strategies like MSA subsampling, guidance during diffusion, or training on MD conformation data can improve sample diversity and enhance ensemble accuracy for certain local dynamics (as in BPTI). However, they may not be sufficient to capture the complex dynamics involved in processes like *apo-holo* conformational changes.

2.2.3 DISTRIBUTION PREDICTION

Distribution prediction assesses a model’s ability to generate distributions that closely resemble a target distribution, such as the empirical distribution obtained from molecular dynamics (MD) simulations. See Section B.2.3 for details. The results are summarized in Table 10 and Table 15. We include reference performances of (1) MD iid: i.i.d. samples from reference MD trajectories and (2) MD 2.5 ns: consecutive samples from the trajectories corresponding to 2.5 ns of simulation.

Table 10: Performance on distribution prediction for ATLAS. 250 conformations were sampled for each protein and the median values across 82 proteins are reported. **These metrics are not available for models that lack side-chain or full backbone information.*

| | Diversity | | Flexibility: <i>Pearson r</i> on | | | Distributional accuracy | | | | |
|----------------------------------|----------------------------|---------------------------------|----------------------------------|------------------------------------|-----------------------------|-------------------------------|------------------------|---------------------------|-----------------------------|--|
| | Pairwise RMSD | *RMSF | Pairwise RMSD \uparrow | *Global RMSF \uparrow | *Per target RMSF \uparrow | *RMWD \downarrow | MD PCA W2 \downarrow | Joint PCA W2 \downarrow | PC sim > 0.5 % \uparrow | |
| MD iid | 2.76 | 1.63 | 0.96 | 0.97 | 0.99 | 0.67 | 0.73 | 0.71 | 93.9 | |
| MD 2.5ns | 1.54 | 0.98 | 0.89 | 0.85 | 0.85 | 2.22 | 1.55 | 1.89 | 36.6 | |
| EigenFold | 5.96 | N/A | -0.03 | N/A | N/A | N/A | 2.31 | 7.96 | 12.2 | |
| MSA-depth256 | 0.83 | 0.53 | 0.25 | 0.34 | 0.59 | 3.60 | 1.79 | 2.91 | 29.3 | |
| Str2Str-ODE ($T_{\max} = 0.1$) | 1.66 | N/A | 0.13 | N/A | N/A | N/A | 2.14 | 4.39 | 6.1 | |
| AlphaFlow-MD | 2.87 | 1.63 | 0.53 | 0.66 | 0.85 | 2.64 | 1.55 | 2.29 | 39.0 | |
| ConfDiff-Open-MD | 3.43 | 2.21 | 0.59 | 0.67 | 0.85 | 2.75 | 1.41 | 2.27 | 35.4 | |
| | Ensemble observables | | | | Quality | | | | | |
| | Weak contacts $J \uparrow$ | Transient contacts $J \uparrow$ | *Exposed residue $J \uparrow$ | *Exposed MI matrix $\rho \uparrow$ | CA clash % \downarrow | *PepBond break % \downarrow | | | | |
| MD iid | 0.90 | 0.80 | 0.93 | 0.56 | 0.0 | 3.4 | | | | |
| MD 2.5ns | 0.62 | 0.45 | 0.64 | 0.25 | 0.0 | 3.4 | | | | |
| EigenFold | 0.36 | 0.19 | N/A | N/A | 5.6 | N/A | | | | |
| MSA-depth256 | 0.30 | 0.29 | 0.36 | 0.06 | 0.0 | 5.5 | | | | |
| Str2Str-ODE ($T_{\max} = 0.1$) | 0.42 | 0.18 | N/A | N/A | 0.0 | 12.1 | | | | |
| AlphaFlow-MD | 0.62 | 0.41 | 0.69 | 0.35 | 0.0 | 22.2 | | | | |
| ConfDiff-Open-MD | 0.63 | 0.39 | 0.65 | 0.33 | 0.5 | 6.5 | | | | |

Overall, generative models trained to sample protein conformations (AlphaFlow, ConfDiff) significantly outperform perturbation-based methods (MSA subsampling and Str2Str), regardless of perturbation levels. Using a strong folding model like AlphaFold2 generally results in higher accuracy. Classifier-free guidance in ConfDiff improved distribution sampling but was less effective than direct fine-tuning on MD data, highlighting the importance of large-scale conformational data for future models. Additionally, the trade-offs between diversity, prediction performance, and sample quality persist: fine-tuning on MD data improves sample diversity and performance for AlphaFlow but decreases sample quality.

AlphaFlow and ConfDiff models fine-tuned on MD data have shown promise in capturing the conformational distributions, achieving performance comparable to that of 2.5 ns MD simulations on some metrics. However, a key goal for these models is to achieve i.i.d. sampling equivalent to long-term MD simulations, and benchmark results reveal a remaining gap in reaching this objective.

3 CONCLUSIONS AND FUTURE WORK

In summary, we present the first comprehensive study evaluating the capabilities of various protein foundation models across eight distinct tasks, with a particular focus on protein design and conformation dynamics. We have developed a unified, multi-metric evaluation framework, which is essential for unbiased assessment of protein foundation models from multiple facets. Based on the performance results, we provide insights and considerations for the development and effective use of protein foundation models, offering guidance for future research.

With the detailed discussion available in the Appendix C, we highlight the key observations from our holistic evaluation as follows: (1) Valid evaluation of protein foundation models requires accurate and comprehensive evaluation metrics; (2) No single model currently excels across all protein design objectives. The choice of model should be carefully aligned with the intended applications; (3) While generative models extended from classic folding models have shown the ability to sample protein conformations, challenges remain in both multiple-state prediction and distribution prediction.

LIMITATIONS AND FUTURE WORK

We acknowledge several limitations and opportunities for enhancement in our current benchmark: (1) The selection of foundation models may not be exhaustive. Future iterations should incorporate additional foundation models to provide a more comprehensive comparison. (2) Inconsistencies in training data across models currently hinder direct comparisons of different model architectures. Future work could address this by standardizing datasets, allowing for more accurate comparisons of architectural performance. (3) The benchmark could be expanded to include a wider range of tasks, further broadening its scope and utility. We are committed to continually refining and expanding ProteinBench. Our vision is for it to evolve into a dynamic, growing benchmark that accelerates progress in the field of protein modeling and design.

540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593

REFERENCES

- Abstract book of the 15th critical assessment of structure prediction*. 2022. URL <https://predictioncenter.org/casp15/doc/CASP15Abstracts.pdf>.
- Josh Abramson, Jonas Adler, Jack Dunger, Richard Evans, Tim Green, Alexander Pritzel, Olaf Ronneberger, Lindsay Willmore, Andrew J Ballard, Joshua Bambrick, et al. Accurate structure prediction of biomolecular interactions with alphafold 3. *Nature*, pp. 1–3, 2024.
- Jared Adolf-Bryfogle, Oleks Kalyuzhnyi, Michael Kubitz, Brian D Weitzner, Xiaozhen Hu, Yumiko Adachi, William R Schief, and Roland L Dunbrack Jr. Rosettaantibodydesign (rabd): A general framework for computational antibody design. *PLoS computational biology*, 14(4):e1006112, 2018.
- Gustaf Ahdriz, Nazim Bouatta, Christina Floristean, Sachin Kadyan, Qinghui Xia, William Gerecke, Timothy J O’Donnell, Daniel Berenberg, Ian Fisk, Niccolò Zanichelli, Bo Zhang, Arkadiusz Nowaczynski, Bei Wang, Marta M Stepniewska-Dziubinska, Shang Zhang, Adegoke Ojewole, Murat Efe Guney, Stella Biderman, Andrew M Watkins, Stephen Ra, Pablo Ribalta Lorenzo, Lucas Nivon, Brian Weitzner, Yih-En Andrew Ban, Peter K Sorger, Emad Mostaque, Zhao Zhang, Richard Bonneau, and Mohammed AlQuraishi. OpenFold: Retraining AlphaFold2 yields new insights into its learning mechanisms and capacity for generalization. *bioRxiv*, 2022. doi: 10.1101/2022.11.20.517210. URL <https://www.biorxiv.org/content/10.1101/2022.11.20.517210>.
- Sarah Alamdari, Nitya Thakkar, Rianne van den Berg, Alex X Lu, Nicolo Fusi, Ava P Amini, and Kevin K Yang. Protein generation with evolutionary diffusion: sequence is all you need. In *Machine Learning for Structural Biology Workshop, NeurIPS 2023*, 2023.
- Rebecca F Alford, Andrew Leaver-Fay, Jeliuzko R Jeliuzkov, Matthew J O’Meara, Frank P DiMaio, Hahnbeom Park, Maxim V Shapovalov, P Douglas Renfrew, Vikram K Mulligan, Kalli Kappel, et al. The rosetta all-atom energy function for macromolecular modeling and design. *Journal of chemical theory and computation*, 13(6):3031–3048, 2017.
- Ethan C. Alley, Grigory Khimulya, Surojit Biswas, Mohammed AlQuraishi, and George M. Church. Unified rational protein engineering with sequence-based deep representation learning. *Nature Methods*, 16:1315–1322, 12 2019. ISSN 1548-7091. doi: 10.1038/s41592-019-0598-1.
- Minkyung Baek, Ivan Anishchenko, Ian R Humphreys, Qian Cong, David Baker, and Frank DiMaio. Efficient and accurate prediction of protein structure using rosettafold2. *BioRxiv*, pp. 2023–05, 2023.
- Helen M Berman, John Westbrook, Zukang Feng, Gary Gilliland, Talapady N Bhat, Helge Weissig, Ilya N Shindyalov, and Philip E Bourne. The protein data bank. *Nucleic acids research*, 28(1): 235–242, 2000.
- Avishek Joey Bose, Tara Akhound-Sadegh, Kilian Fatras, Guillaume Huguet, Jarrid Rector-Brooks, Cheng-Hao Liu, Andrei Cristian Nica, Maksym Korablyov, Michael Bronstein, and Alexander Tong. Se (3)-stochastic flow matching for protein backbone generation. *arXiv preprint arXiv:2310.02391*, 2023.
- Andrew Campbell, Jason Yim, Regina Barzilay, Tom Rainforth, and Tommi Jaakkola. Generative flows on discrete state-spaces: Enabling multimodal flows with applications to protein co-design. In *Forty-first International Conference on Machine Learning*.
- Alexander E Chu, Jinho Kim, Lucy Cheng, Gina El Nesr, Minkai Xu, Richard W Shuai, and Po-Ssu Huang. An all-atom protein generative model. *Proceedings of the National Academy of Sciences*, 121(27):e2311500121, 2024.
- Peter JA Cock, Tiago Antao, Jeffrey T Chang, Brad A Chapman, Cymon J Cox, Andrew Dalke, Iddo Friedberg, Thomas Hamelryck, Frank Kauff, Bartek Wilczynski, et al. Biopython: freely available python tools for computational molecular biology and bioinformatics. *Bioinformatics*, 25(11):1422, 2009.

594 J. Dauparas, I. Anishchenko, N. Bennett, H. Bai, R. J. Ragotte, L. F. Milles, B. I. M. Wicky,
595 A. Courbet, R. J. de Haas, N. Bethel, P. J. Y. Leung, T. F. Huddy, S. Pellock, D. Tischer, F. Chan,
596 B. Koepnick, H. Nguyen, A. Kang, B. Sankaran, A. K. Bera, N. P. King, and D. Baker. Robust
597 deep learning–based protein sequence design using proteinmpnn. *Science*, 378:49–56, 10 2022a.
598 ISSN 0036-8075. doi: 10.1126/science.add2187.

599 Justas Dauparas, Ivan Anishchenko, Nathaniel Bennett, Hua Bai, Robert J Ragotte, Lukas F Milles,
600 Basile IM Wicky, Alexis Courbet, Rob J de Haas, Neville Bethel, et al. Robust deep learning–
601 based protein sequence design using proteinmpnn. *Science*, 378(6615):49–56, 2022b.

602 Diego Del Alamo, Davide Sala, Hassane S Mchaourab, and Jens Meiler. Sampling alternative
603 conformational states of transporters and receptors with alphafold2. *Elife*, 11:e75751, 2022.

604 James Dunbar, Konrad Krawczyk, Jinwoo Leem, Terry Baker, Angelika Fuchs, Guy Georges, Jiye
605 Shi, and Charlotte M. Deane. SAbDab: the structural antibody database. *Nucleic Acids Research*,
606 42(D1):D1140–D1146, 11 2013. ISSN 0305-1048. doi: 10.1093/nar/gkt1043. URL <https://doi.org/10.1093/nar/gkt1043>.

607
608 Zhangyang Gao, Cheng Tan, Pablo Chacón, and Stan Z Li. Pifold: Toward effective and efficient
609 protein inverse folding. *arXiv preprint arXiv:2209.12643*, 2022.

610
611 Zhangyang Gao, Cheng Tan, Yijie Zhang, Xingran Chen, Lirong Wu, and Stan Z Li. Proteinin-
612 vbench: Benchmarking protein inverse folding on diverse tasks, models, and metrics. *Advances*
613 *in Neural Information Processing Systems*, 36, 2024.

614 Tomas Hayes, Roshan Rao, Halil Akin, Nicholas J Sofroniew, Deniz Oktay, Zeming Lin, Robert
615 Verkuil, Vincent Q Tran, Jonathan Deaton, Marius Wiggert, et al. Simulating 500 million years
616 of evolution with a language model. *bioRxiv*, pp. 2024–07, 2024.

617 Brian L. Hie, Varun R. Shanker, Duo Xu, Theodora U. J. Bruun, Payton A. Weidenbacher, Shaogeng
618 Tang, Wesley Wu, John E. Pak, and Peter S. Kim. Efficient evolution of human antibodies from
619 general protein language models. *Nature Biotechnology*, 42:275–283, 2 2024. ISSN 1087-0156.
620 doi: 10.1038/s41587-023-01763-2.

621
622 Chloe Hsu, Robert Verkuil, Jason Liu, Zeming Lin, Brian Hie, om Sercu, Adam Lerer, and Alexan-
623 der Rives. Learning inverse folding from millions of predicted structures. *Proceedings of the 39th*
624 *International Conference on Machine Learning*, 162, 2022. doi: 10.1101/2022.04.10.487779.

625 John B Ingraham, Max Baranov, Zak Costello, Karl W Barber, Wujie Wang, Ahmed Ismail, Vincent
626 Frappier, Dana M Lord, Christopher Ng-Thow-Hing, Erik R Van Vlack, et al. Illuminating protein
627 space with a programmable generative model. *Nature*, 623(7989):1070–1078, 2023.

628 Wengong Jin, Regina Barzilay, and Tommi Jaakkola. Antibody-antigen docking and design via
629 hierarchical structure refinement. In *International Conference on Machine Learning*, pp. 10217–
630 10227. PMLR, 2022.

631
632 Bowen Jing, Stephan Eismann, Patricia Suriana, Raphael John Lamarre Townshend, and Ron Dror.
633 Learning from protein structure with geometric vector perceptrons. In *International Conference*
634 *on Learning Representations*, 2020.

635 Bowen Jing, Ezra Erives, Peter Pao-Huang, Gabriele Corso, Bonnie Berger, and Tommi S Jaakkola.
636 Eigenfold: Generative protein structure prediction with diffusion models. In *ICLR 2023-Machine*
637 *Learning for Drug Discovery workshop*, 2023.

638
639 Bowen Jing, Bonnie Berger, and Tommi Jaakkola. Alphafold meets flow matching for generating
640 protein ensembles. In *Forty-first International Conference on Machine Learning*, 2024.

641 John Jumper, Richard Evans, Alexander Pritzel, Tim Green, Michael Figurnov, Olaf Ronneberger,
642 Kathryn Tunyasuvunakool, Russ Bates, Augustin Žídek, Anna Potapenko, Alex Bridgland,
643 Clemens Meyer, Simon A. A. Kohl, Andrew J. Ballard, Andrew Cowie, Bernardino Romera-
644 Paredes, Stanislav Nikolov, Rishub Jain, Jonas Adler, Trevor Back, Stig Petersen, David Reiman,
645 Ellen Clancy, Michal Zielinski, Martin Steinegger, Michalina Pacholska, Tamas Berghammer, Se-
646 bastian Bodenstern, David Silver, Oriol Vinyals, Andrew W. Senior, Koray Kavukcuoglu, Push-
647 meet Kohli, and Demis Hassabis. Highly accurate protein structure prediction with alphafold.
Nature, 596:583–589, 8 2021. ISSN 0028-0836. doi: 10.1038/s41586-021-03819-2.

648 Xiangzhe Kong, Wenbing Huang, and Yang Liu. Conditional antibody design as 3d equivariant
649 graph translation. In *The Eleventh International Conference on Learning Representations*. ICLR,
650 2022.

651 Xiangzhe Kong, Wenbing Huang, and Yang Liu. End-to-end full-atom antibody design. In *Proceed-*
652 *ings of the 40th International Conference on Machine Learning*, pp. 17409–17429, 2023.

654 Daniel Kovtun, Mehmet Akdel, Alexander Goncarenco, Guoqing Zhou, Graham Holt, David
655 Baugher, Dejun Lin, Yusuf Adeshina, Thomas Castiglione, Xiaoyun Wang, et al. Pinder: The
656 protein interaction dataset and evaluation resource. *bioRxiv*, pp. 2024–07, 2024.

657 Rohith Krishna, Jue Wang, Woody Ahern, Pascal Sturmfels, Preetham Venkatesh, Indrek Kalvet,
658 Gyu Rie Lee, Felix S. Morey-Burrows, Ivan Anishchenko, Ian R. Humphreys, Ryan McHugh,
659 Dionne Vafeados, Xinting Li, George A. Sutherland, Andrew Hitchcock, C. Neil Hunter, Alex
660 Kang, Evans Brackenbrough, Asim K. Bera, Minkyung Baek, Frank DiMaio, and David Baker.
661 Generalized biomolecular modeling and design with rosettafold all-atom. *Science*, 384, 4 2024.
662 ISSN 0036-8075. doi: 10.1126/science.adl2528.

663 Brian Kuhlman and Philip Bradley. Advances in protein structure prediction and design. *Nature*
664 *Reviews Molecular Cell Biology*, 20:681–697, 11 2019. ISSN 1471-0072. doi: 10.1038/
665 s41580-019-0163-x.

667 Marie-Paule Lefranc, Veronique Giudicelli, Chantal Ginestoux, Joumana Jabado-Michaloud, Geraldine
668 Folch, Fatena Bellahcene, Yan Wu, Elodie Gemrot, Xavier Brochet, Jero`me Lane, et al.
669 Imgt®, the international immunogenetics information system®. *Nucleic acids research*, 37
670 (suppl_1):D1006–D1012, 2009.

671 Yeqing Lin and Mohammed AlQuraishi. Generating novel, designable, and diverse protein struc-
672 tures by equivariantly diffusing oriented residue clouds. *arXiv preprint arXiv:2301.12485*, 2023.

673 Zeming Lin, Halil Akin, Roshan Rao, Brian Hie, Zhongkai Zhu, Wenting Lu, Nikita Smetanin,
674 Robert Verkuil, Ori Kabeli, Yaniv Shmueli, Allan dos Santos Costa, Maryam Fazel-Zarandi, Tom
675 Sercu, Salvatore Candido, and Alexander Rives. Evolutionary-scale prediction of atomic-level
676 protein structure with a language model. *Science*, 379:1123–1130, 3 2023a. ISSN 0036-8075.
677 doi: 10.1126/science.ade2574.

678 Zeming Lin, Halil Akin, Roshan Rao, Brian Hie, Zhongkai Zhu, Wenting Lu, Nikita Smetanin,
679 Robert Verkuil, Ori Kabeli, Yaniv Shmueli, et al. Evolutionary-scale prediction of atomic-level
680 protein structure with a language model. *Science*, 379(6637):1123–1130, 2023b.

682 Sidney Lyayuga Lisanza, Jake Merle Gershon, Sam Tipps, Lucas Arnoldt, Samuel Hendel,
683 Jeremiah Nelson Sims, Xinting Li, and David Baker. Joint generation of protein sequence and
684 structure with rosettafold sequence space diffusion. *bioRxiv*, pp. 2023–05, 2023.

685 Haiyan Liu, Yufeng Liu, and Linghui Chen. Diffusion in a quantized vector space generates non-
686 idealized protein structures and predicts conformational distributions. *bioRxiv*, pp. 2023–11,
687 2023.

688 Jiarui Lu, Bozitao Zhong, Zuobai Zhang, and Jian Tang. Str2str: A score-based framework for
689 zero-shot protein conformation sampling. In *The Twelfth International Conference on Learning*
690 *Representations*, 2024.

692 Shitong Luo, Yufeng Su, Xingang Peng, Sheng Wang, Jian Peng, and Jianzhu Ma. Antigen-specific
693 antibody design and optimization with diffusion-based generative models for protein structures.
694 *Advances in Neural Information Processing Systems*, 35:9754–9767, 2022.

695 Ali Madani, Ben Krause, Eric R. Greene, Subu Subramanian, Benjamin P. Mohr, James M. Holton,
696 Jose Luis Olmos, Caiming Xiong, Zachary Z. Sun, Richard Socher, James S. Fraser, and Nikhil
697 Naik. Large language models generate functional protein sequences across diverse families. *Nature*
698 *Biotechnology*, 41:1099–1106, 8 2023. ISSN 1087-0156. doi: 10.1038/s41587-022-01618-2.

700 Valerio Mariani, Marco Biasini, Alessandro Barbato, and Torsten Schwede. Iddt: a local
701 superposition-free score for comparing protein structures and models using distance difference
tests. *Bioinformatics*, 29(21):2722–2728, 2013.

702 Milot Mirdita, Konstantin Schütze, Yoshitaka Moriwaki, Lim Heo, Sergey Ovchinnikov, and Martin
703 Steinegger. Colabfold: making protein folding accessible to all. *Nature methods*, 19(6):679–682,
704 2022.

705 Erik Nijkamp, Jeffrey A. Ruffolo, Eli N. Weinstein, Nikhil Naik, and Ali Madani. Progen2: Ex-
706 ploring the boundaries of protein language models. *Cell Systems*, 14:968–978.e3, 11 2023. ISSN
707 24054712. doi: 10.1016/j.cels.2023.10.002.

708 Pascal Notin, Aaron Kollasch, Daniel Ritter, Lood Van Niekerk, Steffanie Paul, Han Spinner, Nathan
709 Rollins, Ada Shaw, Rose Orenbuch, Ruben Weitzman, et al. Proteingym: Large-scale benchmarks
710 for protein fitness prediction and design. *Advances in Neural Information Processing Systems*, 36,
711 2024.

712 Milong Ren, Chungong Yu, Dongbo Bu, and Haicang Zhang. Accurate and robust protein sequence
713 design with carbondesign. *Nature Machine Intelligence*, 6(5):536–547, 2024.

714 Alexander Rives, Joshua Meier, Tom Sercu, Siddharth Goyal, Zeming Lin, Jason Liu, Demi Guo,
715 Myle Ott, C. Lawrence Zitnick, Jerry Ma, and Rob Fergus. Biological structure and function
716 emerge from scaling unsupervised learning to 250 million protein sequences. *Proceedings of the
717 National Academy of Sciences*, 118, 4 2021. ISSN 0027-8424. doi: 10.1073/pnas.2016239118.

718 Xavier Robin, Juergen Haas, Rafal Gumienny, Anna Smolinski, Gerardo Tauriello, and Torsten
719 Schwede. Continuous automated model evaluation (cameo)—perspectives on the future of fully
720 automated evaluation of structure prediction methods. *Proteins: Structure, Function, and Bioin-
721 formatics*, 89:1977–1986, 12 2021. ISSN 0887-3585. doi: 10.1002/prot.26213.

722 Jeffrey A Ruffolo, Jeffrey J Gray, and Jeremias Sulam. Deciphering antibody affinity maturation
723 with language models and weakly supervised learning. In *Machine Learning for Structural Biol-
724 ogy Workshop, NeurIPS 2021.*, 2021.

725 Jeffrey A Ruffolo, Lee-Shin Chu, Sai Pooja Mahajan, and Jeffrey J Gray. Fast, accurate antibody
726 structure prediction from deep learning on massive set of natural antibodies. *Nature communica-
727 tions*, 14(1):2389, 2023.

728 Tadeo Saldaño, Nahuel Escobedo, Julia Marchetti, Diego Javier Zea, Juan Mac Donagh, Ana Julia
729 Velez Rueda, Eduardo Gonik, Agustina García Melani, Julieta Novomisky Nechcoff, Martín N
730 Salas, et al. Impact of protein conformational diversity on alphafold predictions. *Bioinformatics*,
731 38(10):2742–2748, 2022.

732 David E Shaw, Paul Maragakis, Kresten Lindorff-Larsen, Stefano Piana, Ron O Dror, Michael P
733 Eastwood, Joseph A Bank, John M Jumper, John K Salmon, Yibing Shan, et al. Atomic-level
734 characterization of the structural dynamics of proteins. *Science*, 330(6002):341–346, 2010.

735 Jung-Eun Shin, Adam J. Riesselman, Aaron W. Kollasch, Conor McMahon, Elana Simon, Chris
736 Sander, Aashish Manglik, Andrew C. Kruse, and Debora S. Marks. Protein design and variant
737 prediction using autoregressive generative models. *Nature Communications*, 12:2403, 4 2021.
738 ISSN 2041-1723. doi: 10.1038/s41467-021-22732-w.

739 Martin Steinegger and Johannes Söding. Mmseqs2 enables sensitive protein sequence searching for
740 the analysis of massive data sets. *Nature biotechnology*, 35(11):1026–1028, 2017.

741 Kiera H. Sumida, Reyes Núñez-Franco, Indrek Kalvet, Samuel J. Pellock, Basile I. M. Wicky,
742 Lukas F. Milles, Justas Dauparas, Jue Wang, Yakov Kipnis, Noel Jameson, Alex Kang, Josh-
743 myn De La Cruz, Banumathi Sankaran, Asim K. Bera, Gonzalo Jiménez-Osés, and David Baker.
744 Improving protein expression, stability, and function with proteinmpnn. *Journal of the American
745 Chemical Society*, 146:2054–2061, 1 2024. ISSN 0002-7863. doi: 10.1021/jacs.3c10941.

746 Baris E. Suzek, Yuqi Wang, Hongzhan Huang, Peter B. McGarvey, and Cathy H. Wu. Uniref
747 clusters: a comprehensive and scalable alternative for improving sequence similarity searches.
748 *Bioinformatics*, 31:926–932, 3 2015. ISSN 1367-4811. doi: 10.1093/bioinformatics/btu739.

749 Brian L Trippe, Jason Yim, Doug Tischer, David Baker, Tamara Broderick, Regina Barzilay, and
750 Tommi Jaakkola. Diffusion probabilistic modeling of protein backbones in 3d for the motif-
751 scaffolding problem. *arXiv preprint arXiv:2206.04119*, 2022.

756 Michel van Kempen, Stephanie S Kim, Charlotte Tumescheit, Milot Mirdita, Cameron LM Gilchrist,
757 Johannes Söding, and Martin Steinegger. Foldseek: fast and accurate protein structure search.
758 *Biorxiv*, pp. 2022–02, 2022.

759 Yann Vander Meersche, Gabriel Cretin, Aria Gheeraert, Jean-Christophe Gelly, and Tatiana Ga-
760 lochkina. Atlas: protein flexibility description from atomistic molecular dynamics simulations.
761 *Nucleic acids research*, 52(D1):D384–D392, 2024.

762 Mihaly Varadi, Stephen Anyango, Mandar Deshpande, Sreenath Nair, Cindy Natassia, Galabina
763 Yordanova, David Yuan, Oana Stroe, Gemma Wood, Agata Laydon, et al. Alphafold protein
764 structure database: massively expanding the structural coverage of protein-sequence space with
765 high-accuracy models. *Nucleic acids research*, 50(D1):D439–D444, 2022.

766 Robert Verkuil, Ori Kabeli, Yilun Du, Basile IM Wicky, Lukas F Milles, Justas Dauparas, David
767 Baker, Sergey Ovchinnikov, Tom Sercu, and Alexander Rives. Language models generalize be-
768 yond natural proteins. *BioRxiv*, pp. 2022–12, 2022.

769 Chentong Wang, Yannan Qu, Zhangzhi Peng, Yukai Wang, Hongli Zhu, Dachuan Chen, and Longx-
770 ing Cao. Proteus: exploring protein structure generation for enhanced designability and efficiency.
771 *bioRxiv*, pp. 2024–02, 2024a.

772 Chuanrui Wang, Bozitao Zhong, Zuobai Zhang, Narendra Chaudhary, Sanchit Misra, and Jian
773 Tang. Pdb-struct: A comprehensive benchmark for structure-based protein design. *arXiv preprint*
774 *arXiv:2312.00080*, 2023.

775 Xinyou Wang, Zaixiang Zheng, Fei Ye, Dongyu Xue, Shujian Huang, and Quanquan Gu. Diffusion
776 language models are versatile protein learners. In *International conference on machine learning*,
777 2024b.

778 Yan Wang, Lihao Wang, Yuning Shen, Yiqun Wang, Huizhuo Yuan, Yue Wu, and Quanquan Gu.
779 Protein conformation generation via force-guided se (3) diffusion models. In *Forty-first Interna-*
780 *tional Conference on Machine Learning*, 2024c.

781 Joseph L. Watson, David Juergens, Nathaniel R. Bennett, Brian L. Trippe, Jason Yim, Helen E.
782 Eisenach, Woody Ahern, Andrew J. Borst, Robert J. Ragotte, Lukas F. Milles, Basile I. M.
783 Wicky, Nikita Hanikel, Samuel J. Pellock, Alexis Courbet, William Sheffler, Jue Wang, Preetham
784 Venkatesh, Isaac Sappington, Susana Vázquez Torres, Anna Lauko, Valentin De Bortoli, Emile
785 Mathieu, Sergey Ovchinnikov, Regina Barzilay, Tommi S. Jaakkola, Frank DiMaio, Minkyung
786 Baek, and David Baker. De novo design of protein structure and function with rfdiffusion. *Nature*,
787 620:1089–1100, 8 2023a. ISSN 0028-0836. doi: 10.1038/s41586-023-06415-8.

788 Joseph L Watson, David Juergens, Nathaniel R Bennett, Brian L Trippe, Jason Yim, Helen E Eise-
789 nach, Woody Ahern, Andrew J Borst, Robert J Ragotte, Lukas F Milles, et al. De novo design of
790 protein structure and function with rfdiffusion. *Nature*, 620(7976):1089–1100, 2023b.

791 Hannah K Wayment-Steele, Adedolapo Ojoawo, Renee Otten, Julia M Apitz, Warintra Pitsawong,
792 Marc Hömberger, Sergey Ovchinnikov, Lucy Colwell, and Dorothee Kern. Predicting multiple
793 conformations via sequence clustering and alphafold2. *Nature*, 625(7996):832–839, 2024.

794 Kevin E Wu, Kevin K Yang, Rianne van den Berg, Sarah Alamdari, James Y Zou, Alex X Lu, and
795 Ava P Amini. Protein structure generation via folding diffusion. *Nature communications*, 15(1):
796 1059, 2024a.

797 Luhuan Wu, Brian Trippe, Christian Naeseth, David Blei, and John P Cunningham. Practical and
798 asymptotically exact conditional sampling in diffusion models. *Advances in Neural Information*
799 *Processing Systems*, 36, 2024b.

800 Ruidong Wu, Fan Ding, Rui Wang, Rui Shen, Xiwen Zhang, Shitong Luo, Chenpeng Su, Zuofan
801 Wu, Qi Xie, Bonnie Berger, et al. High-resolution de novo structure prediction from primary
802 sequence. *BioRxiv*, pp. 2022–07, 2022.

803 Jason Yim, Andrew Campbell, Andrew YK Foong, Michael Gastegger, José Jiménez-Luna, Sarah
804 Lewis, Victor Garcia Satorras, Bastiaan S Veeling, Regina Barzilay, Tommi Jaakkola, et al. Fast
805 protein backbone generation with se (3) flow matching. *arXiv preprint arXiv:2310.05297*, 2023.

- 810 Jason Yim, Andrew Campbell, Emile Mathieu, Andrew YK Foong, Michael Gastegger, José
811 Jiménez-Luna, Sarah Lewis, Victor Garcia Satorras, Bastiaan S Veeling, Frank Noé, et al. Im-
812 proved motif-scaffolding with se (3) flow matching. *ArXiv*, 2024.
- 813
- 814 Yang Zhang and Jeffrey Skolnick. Scoring function for automated assessment of protein structure
815 template quality. *Proteins: Structure, Function, and Bioinformatics*, 57(4):702–710, 2004.
- 816 Yang Zhang and Jeffrey Skolnick. Tm-align: a protein structure alignment algorithm based on the
817 tm-score. *Nucleic acids research*, 33(7):2302–2309, 2005.
- 818
- 819 Shuxin Zheng, Jiyang He, Chang Liu, Yu Shi, Ziheng Lu, Weitao Feng, Fusong Ju, Jiayi Wang,
820 Jianwei Zhu, Yaosen Min, et al. Predicting equilibrium distributions for molecular systems with
821 deep learning. *Nature Machine Intelligence*, pp. 1–10, 2024.
- 822 Zaixiang Zheng, Yifan Deng, Dongyu Xue, Yi Zhou, Fei Ye, and Quanquan Gu. Structure-informed
823 language models are protein designers. In *International conference on machine learning*, pp.
824 42317–42338. PMLR, 2023.
- 825
- 826 Xiangxin Zhou, Dongyu Xue, Ruizhe Chen, Zaixiang Zheng, Liang Wang, and Quanquan Gu.
827 Antigen-specific antibody design via direct energy-based preference optimization. In *ICML 2024*
828 *Workshop AI4Science*, 2024.

829 A OVERVIEW OF PROTEIN FOUNDATION MODEL BENCHMARKS

830 A.1 GENERAL BENCHMARK DESIGN RATIONALE

831 The field of protein three-dimensional structure prediction has witnessed remarkable progress, ex-
832 emplified by established benchmarks like CASP and CAMEO, and breakthrough methodologies
833 including AlphaFold series, RosettaFold, ESMFold, and OmegaFold. While structure prediction fo-
834 cuses on determining protein structures from known sequences, protein design addresses the inverse
835 challenge: creating sequences that will fold into desired structures or achieve specific functions.
836 Despite growing interest in protein design, the field has been hampered by the absence of a compre-
837 hensive benchmark, with existing evaluations primarily targeting specialized tasks, as documented
838 in Appendix Table 1. A similar limitation exists in conformational dynamics research. Our work
839 addresses these gaps by introducing the first comprehensive benchmark focusing on protein design
840 and conformation prediction.

841 In our benchmark, protein design is categorized into five distinct areas, following the natural
842 sequence-structure-function hierarchy. This begins with sequence design, focusing on optimizing
843 amino acid sequences for stable folding, and progresses to backbone design, which involves en-
844 gineering the overall protein architecture. The more complex sequence-structure co-design task
845 requires simultaneous optimization of both sequence and structure. At the functional level, mo-
846 tif scaffolding involves incorporating functional motifs into stable scaffolds, while antibody design
847 represents a specialized application focusing on engineering antibody structures and sequences for
848 antigen binding, particularly crucial for therapeutic development.

849 The conformation prediction component is similarly structured into three distinct categories, reflect-
850 ing increasing levels of complexity in protein dynamics. Single conformation prediction focuses
851 on identifying the lowest energy state among possible conformations. Multiple conformation pre-
852 diction addresses the more complicated challenge of predicting discrete conformational states. The
853 most sophisticated category, conformational distribution prediction, tackles the complex task of pre-
854 dicting probability distributions of conformations, essential for understanding proteins with dynamic
855 structural ensembles.

856 A.2 OVERVIEW OF EXISTING BENCHMARKS

857 In this section, we provide a comprehensive overview of existing benchmarks for protein foundation
858 models. Table 11 illustrates the current landscape of these benchmarks, revealing significant limi-
859 tations in the scope and applicability. The majority of existing benchmarks are narrowly focused,
860 primarily addressing task-specific evaluations rather than offering a holistic assessment of protein
861 foundation models.

862 Notably, our proposed ProteinBench stands out by offering the most comprehensive coverage across
863 various tasks. It encompasses a wide range of evaluations, including inverse folding, backbone

design, sequence design, structure-sequence co-design, and antibody design in the protein design domain, as well as single-state folding, and multiple-state prediction in the conformational dynamics domain.

Table 11: A comparison of benchmarks for protein fundamental tasks.

| Benchmark | Protein Design | | | | | | Protein Conformation Prediction | | |
|------------------------------------|-----------------|-----------------|-----------------|--------------------|-------------------|-----------------|---------------------------------|---------------------------|-------------------------|
| | Inverse Folding | Backbone Design | Sequence Design | Struc-Seq Codesign | Motif scaffolding | Antibody Design | Folding (single-state) | Multiple State Prediction | Distribution Prediction |
| PDB-Struct (Wang et al., 2023) | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| ProteinInvbench (Gao et al., 2024) | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| RFDiffusion (Watson et al., 2023b) | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✓ | ✗ | ✗ |
| CASP (cas, 2022) | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ |
| CAMEO (Robin et al., 2021) | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ |
| PINDER (Kovtun et al., 2024) | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ |
| ProteinBench | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

B DETAILS ON BENCHMARKING EVALUATIONS

In this section, we provide detailed discussions for each task addressed by various protein foundation models, as shown in Table 1. Our focus will be on the following aspects:

[Task Definition] A detailed description of the task, including its objectives and relevance to protein science. Specification of the input data format and expected output for each task. [The impact of the task for protein is provided.](#)

[Evaluation Metrics] Justification and description of the metrics used to assess model performance, including quality, novelty, diversity, and robustness measures. [For each specific task, we provided a detailed thought process behind the metric selection and detailed implementation information.](#)

[Datasets] Overview of the datasets used for each task, including their size, diversity, and any pre-processing steps applied. [Detailed considerations of datasets, such as dataset impacts, are provided.](#)

[Model Implementations] We place the detailed implementation information for the evaluated methods in this part.

[Extended Explanations and Discussion on Model Performance] Due to space limitations in the main text, we provide an additional explanation and discussion of the performance of specific methods here.

B.1 PROTEIN DESIGN

B.1.1 INVERSE FOLDING

[Task Definition] Inverse folding is a fundamental task in protein engineering aimed at designing amino acid sequences that can fold into predetermined structural configurations. This task is essential for various applications, including capturing evolutionary distribution of protein sequences (Zheng et al., 2023), facilitating de novo protein design (Dauparas et al., 2022b), and optimizing protein stability for therapeutic and industrial purposes (Sumida et al., 2024).

[Evaluation Metrics] A key factor in inverse folding is the diverse range of downstream objectives, each requiring specific datasets and evaluation approaches. To provide a comprehensive assessment, we evaluate model performance separately for these distinct objectives. For assessing evolutionary distribution capture, we employ datasets comprising native protein structures. To evaluate sequence design capabilities for novel structures, we utilize datasets of protein backbones generated by RFDiffusion (Watson et al., 2023). Additionally, we incorporate the pLDDT metric to evaluate the predicted folding stability of designed sequences, providing insights into their structural reliability.

For the inverse folding task, metrics for evaluation have evolved over time. ProteinMPNN initially employed amino acid recovery (AAR) as the primary evaluation metric (Dauparas et al., 2022a). More recent studies have introduced structure-based self-consistency TM-score (scTM) as an additional metric for this task (Gao et al., 2024; Ren et al., 2024). Based on these previous studies, we recognize that both metrics provide valuable and complementary insights into model performance. AAR measures sequence-level accuracy while scTM assesses the structural validity of the designed sequences. Performance in protein sequence design is assessed using multiple complementary metrics.

- 918
- 919
- 920
- 921
- 922
- 923
- 924
- 925
- 926
- 927
- 928
- 929
- 930
- 931
- 932
- 933
- 934
- 935
- 936
- 937
- 938
- 939
- **Sequence Recovery** Amino Acid Recovery Rate (AAR), measures the sequence recovery rate of designed proteins and quantifies how well the design method can recapitulate evolutionarily conserved sequence patterns associated with specific structural motifs. While it is highly efficient for evolutionary design evaluation, AAR is limited to cases with known ground truth sequences and cannot assess the refoldability of de novo designed sequences.
 - **Refoldability** self-consistency TM-score (scTM), assesses the structural refoldability of designed sequences and has been widely adopted in the field for structural validation. This measure evaluates the structural similarity between the target backbone and the predicted structure of the designed sequence. scTM can be applied to both native and de novo designed sequences, making it more versatile. The prediction is performed using AlphaFold2 (Jumper et al., 2021). We used the ColabFold implementation Mirdita et al. (2022) for AlphaFold2 inference, with input MSAs obtained using the Colab pipeline. Specifically, the designed sequences are input into AlphaFold2 in the MSA alignment mode. For each prediction round, five structures are generated, and the candidate structure with the highest pLDDT confidence score is selected for comparison with the targeted structure. Similarity is quantified using self-consistency template modeling score (scTM) (Trippé et al., 2022) and self-consistency root-mean-square deviation (scRMSD), providing insight into how well the designed sequence would fold into the intended structure.
 - **Stability** Stability is assessed using the predicted local distance difference test (pLDDT), which is also calculated by AlphaFold2 in the same MSA alignment mode used for the scTM score. The pLDDT score serves as a proxy for the predicted stability of the designed protein, as utilized in Dauparas et al. (2022a). We have observed that removing the MSA alignment may yield optimal results for pLDDT, and we plan to update our findings accordingly in future analyses.

940 **[Datasets]** Typically, inverse folding methods are trained using CATH or PDB datasets. To prevent data leakage, we utilized newly released PDB structures collected from CASP and CAMEO, as well as de novo designed backbones that have not been included in any training sets. Evaluations were conducted on different datasets targeting two distinct objectives of structure-based sequence design.

- 941
- 942
- 943
- 944
- 945
- 946
- 947
- 948
- 949
- 950
- 951
- 952
- 953
- 954
- 955
- 956
- 957
- 958
- 959
- 960
- 961
- **Capture the native evolutionary distribution** We evaluated two independent datasets containing newly released experimentally well-determined PDB structures: CASP15 (cas, 2022) and CAMEO (Robin et al., 2021). We collected new structures from the ongoing CAMEO assessment between January and July 2024, resulting in a total of 332 complex structures. Additionally, 32 protein structures were collected from CASP15, which includes only protein entities, excluding nucleic acids or ligands. These datasets mainly comprise native single-chain protein structures and sequences, making it optimal for evaluating evolutionary information capture and enabling assessment of natural sequence recovery.
 - **De novo protein design** RFdiffusion (Watson et al., 2023a) was used to unconditionally generate backbones of varying lengths: specifically, 100, 200, 300, 400, and 500 residues. For each length, 10 different structures were randomly sampled, using a sampling temperature of 0.1 for all methods. The designability of these sequences was evaluated using AlphaFold2, with the scTM score and pLDDT metrics serving as the primary assessment criteria. Existing benchmarks for inverse folding, such as PDB-Struct (Wang et al., 2023) and ProteinInvbench (Gao et al., 2024), provide standardized protein structure sets for evaluating inverse folding methods. While these benchmarks have significantly contributed to the field’s advancement, there is a growing need for more comprehensive evaluation frameworks. These expanded evaluations should align more closely with diverse user objectives in protein design, encompassing aspects like accuracy in capturing natural evolutionary distributions and robustness in de novo backbone-based sequence design.

962 **Model implementations** A sampling temperature of 0.1 was used for each method to generate sequences. While this value balances sequence diversity and quality, optimal temperatures may vary across inverse folding methods. For each structure, one generated sequence was predicted for performance evaluation.

- 963
- 964
- 965
- 966
- 967
- 968
- 969
- 970
- 971
- ProteinMPNN (Dauparas et al., 2022a): We follow the official repository and instructions for inference, with the sampling temperature set to 0.1. The default model weight `v_48_020.pt` is used.
 - ESM-IF1 (Hsu et al., 2022): We use the public ESM repository for inference.
 - LM-DESIGN (Zheng et al., 2023): We used the official repository with the model `lm_design_esm2_650m`.

- 972 • ESM3 (Hayes et al., 2024): We follow the official repository with model `esm3-open-small`,
973 which has 1.4B parameters.

974 [Extended Explanations and Discussion on Model Performance]

- 976 • **Dataset Characteristics Impact Performance** Our evaluation spans two dataset types: high-
977 quality experimental structures (CASP/CAMEO) and computational de novo structures containing
978 inherent noise. Models performing well on the more challenging de novo structures demonstrate
979 superior robustness, as they must overcome structural uncertainties while maintaining design ac-
980 curacy.
- 981 • **Training Strategy Influences Robustness** ProteinMPNN’s approach of incorporating backbone
982 noise during training proves highly effective. Our results confirm their findings that increased
983 training noise correlates with improved model robustness. This is evidenced by ProteinMPNN’s
984 superior performance in de novo backbone-based sequence design, validating backbone noise
985 augmentation as an effective strategy for enhancing model resilience.

987 B.1.2 PROTEIN BACKBONE DESIGN

988 [Task Definition] Protein backbone design is a classical protein design problem, centered on
989 developing new protein folds to meet de novo design objectives. It is widely accepted that novel
990 structures can approximate new functions. As such, the backbone design task is crucial for
991 expanding the repertoire of protein structures beyond those found in nature, offering significant
992 applications in areas such as drug discovery, biomaterials, and therapeutics. With de novo designed
993 protein backbones, inverse folding methods can be employed to generate the corresponding
994 sequences.

995 [Evaluation Metrics] The rapid development of protein backbone design methods in recent years
996 has been accompanied by inconsistent evaluation practices across different studies. While some
997 researchers report quality in terms of designability, others utilize scTM scores, making it difficult
998 to draw meaningful comparisons between methods. To address this fragmentation in the field, our
999 benchmark implements a comprehensive evaluation framework with standardized metrics. This
1000 unified approach enables both fair comparisons between methods and thorough assessment of their
1001 performance across multiple aspects of backbone design quality.

1002 Building on previous studies (Trippe et al., 2022; Lin & AlQuraishi, 2023; Yim et al., 2023; Watson
1003 et al., 2023b), we evaluate backbone design through multiple criteria that assess the quality, diversity,
1004 and novelty of generated structures.

- 1005 • **Quality** We utilize ProteinMPNN (Dauparas et al., 2022a) to generate eight different sequences
1006 for each backbone structure, which are unconditionally sampled from various methods. The struc-
1007 tures of these eight sequences are predicted using ESMFold (Lin et al., 2023a). We employ self-
1008 consistency TM-score (scTM) and self-consistency RMSD (scRMSD) to measure structural re-
1009 foldability. For each backbone, we select the sequence with the maximum scTM score. For each
1010 method, we unconditionally sample 100 different backbones and report the median scTM and
1011 scRMSD.
- 1012 • **Novelty** Equally important are novelty metrics, which gauge the method’s capacity to explore
1013 new structural space beyond known protein folds. The metrics measuring the novelty of generated
1014 structures were introduced in recent studies (Yim et al., 2023; Campbell et al.). This aspect is
1015 evaluated using two key metrics: The maximum TM-score obtained when comparing designed
1016 structures to existing entries in the RCSB Protein Data Bank (PDB) (Berman et al., 2000). This
1017 comparison is performed using Foldseek with a threshold TM-score of less than 0.5 (van Kempen
1018 et al., 2022).
- 1019 • **Diversity** Two metrics were used to evaluate diversity: (a) We calculate the average pairwise
1020 maximum TM-scores among the designed structures. A lower TM-score indicates better diversity.
1021 (b) The number of distinct structural clusters identified within the set of designed backbones was
1022 also determined using Foldseek (van Kempen et al., 2022) with a TM-score threshold less than
1023 0.5. More clusters stand for higher diversity. These diversity metrics help quantify the range of
1024
1025

Table 12: Performance of backbone design models evaluated using 200, and 400 amino acids in lengths. The reported results are the medium of repetitive experiments. We use bold text to highlight the best and suboptimal results for each metric. For the novelty and diversity metrics, we only highlight results with the corresponding scTM score higher than 0.5.

| | length 200 | | | | | length 400 | | | | |
|--------------------|--------------|--------------|--------------|---------------|--------------|--------------|-------------|--------------|---------------|--------------|
| | Quality | | Novelty | Diversity | | Quality | | Novelty | Diversity | |
| | scTM ↑ | scRMSD ↓ | Max TM ↓ | pairwise TM ↓ | Max Clust. ↑ | scTM ↑ | scRMSD ↓ | Max TM ↓ | pairwise TM ↓ | Max Clust. ↑ |
| Native PDBs | 0.974 | 0.674 | N/A | 0.278 | 0.790 | 0.970 | 1.085 | N/A | 0.261 | 0.840 |
| RFdiffusion | 0.982 | 0.617 | 0.638 | 0.363 | 0.64 | 0.927 | 2.12 | 0.634 | 0.356 | 0.720 |
| FrameFlow | 0.953 | 1.02 | 0.648 | 0.458 | 0.800 | 0.805 | 4.46 | 0.620 | 0.4196 | 0.920 |
| Chroma | 0.892 | 1.776 | 0.674 | 0.346 | 0.620 | 0.761 | 4.891 | 0.626 | 0.304 | 0.95 |
| FrameDiff (latest) | 0.893 | 1.789 | 0.689 | 0.464 | 0.260 | 0.800 | 4.324 | 0.668 | 0.467 | 0.330 |
| FoldFlow1 (base) | 0.529 | 7.108 | 0.579 | 0.430 | 0.950 | 0.415 | 11.743 | 0.525 | 0.357 | 1.00 |
| FoldFlow1 (sfm) | 0.619 | 5.270 | 0.586 | 0.433 | 0.980 | 0.398 | 11.135 | 0.534 | 0.372 | 0.99 |
| FoldFlow1 (ot) | 0.528 | 6.877 | 0.582 | 0.392 | 0.900 | 0.418 | 10.78 | 0.559 | 0.365 | 0.99 |
| Genie | 0.367 | 13.699 | 0.431 | 0.264 | 1.00 | 0.251 | 24.453 | 0.238 | 0.229 | 1.00 |

unique structures the design method can produce, ensuring that it’s not simply recreating known folds but generating a varied repertoire of protein backbones.

[Datasets] Protein backbone design is a generative task, whose primary objective is to map the overall distribution of the training set accurately. To conduct a comprehensive performance analysis of protein structure generation, we compare the models’ performance against the distribution of real PDB structure data. Specifically, we randomly sampled 100 high-resolution experimental structures from the Protein Data Bank (PDB) to serve as references for the data distribution. To ensure diversity, we iteratively removed structures with the highest TM-score compared to others until we arrived at a final set of 100 distinct structures. This approach provides a representative snapshot of the single-chain structural distribution within the PDB, serving as a benchmark for evaluating the performance of generative models in capturing the true distribution of protein structures.

[Model implementations] To ensure comprehensive evaluation, we test each method’s ability to perform unconditional monomer generation across diverse protein sizes. We follow the official repository and instructions for inference. The generation process is constrained only by specified target lengths, which we set at 50, 100, 200, 300, 400, and 500 residues. This range allows us to assess method performance across both small proteins and larger, more complex structures.

[Extended Explanations and Discussion on Model Performance] A notable observation across different backbone design methods reveals an inverse relationship between structural quality and diversity: as methods generate more diverse and novel structures, the quality of the generated backbones tends to decrease. We emphasize that structural quality should be considered the primary metric, as diversity and novelty become meaningful only when the generated structures maintain sufficient quality. Without adequate structural quality, high diversity or novelty scores may simply reflect the generation of unrealistic or physically implausible conformations.

In the revised manuscript, we have expanded our evaluation to include Proteus’s performance across multiple protein lengths (100, 200, 300, and 500 residues). Our analysis reveals that Proteus demonstrates superior design quality for long-chain backbone design (500 residues), achieving a scTM score of 0.90 compared to RFdiffusion’s 0.79. However, we observed a significant decline in structural diversity for Proteus when designing longer chains. At 300 residues, Proteus shows a diversity score of 0.34 vs. RFdiffusion of 0.65. At 500 residues, Proteus shows a diversity score of 0.34 vs. RFdiffusion of 0.89. Case analysis revealed that Proteus tends to generate structures limited to three categories, predominantly characterized by helical tandem repeats, confirming our diversity metric findings.

[Additional results for backbone design]

In this section, we provide more detailed evaluation results of protein backbone design across additional lengths 200 and 400. The results are shown in Table.12.

B.1.3 PROTEIN SEQUENCE DESIGN

[Task Definition] Protein sequence design aims to generate amino acid sequences with desired properties, including quality, diversity, and novelty. The task encompasses both sequence-level

1080 evaluation and assessment of structural characteristics of the generated sequences, making it
1081 fundamental for various applications in protein engineering and therapeutic development.
1082

1083 **[Evaluation Metrics]** The evaluation of protein sequence design requires a multi-faceted approach
1084 that considers both sequence-level properties and structural characteristics. Sequence-level as-
1085 sessment should verify that generated sequences follow natural protein patterns, while structural
1086 evaluation ensures the designs are likely to fold into stable, well-defined conformations. This
1087 comprehensive evaluation strategy helps validate both the theoretical and practical utility of
1088 designed sequences.
1089

1090 The evaluation of protein sequence design requires a multi-faceted approach that considers both
1091 sequence-level properties and structural characteristics. Sequence-level assessment should verify
1092 that generated sequences follow natural protein patterns, while structural evaluation ensures the
1093 designs are likely to fold into stable, well-defined conformations. This comprehensive evaluation
1094 strategy helps validate both the theoretical and practical utility of designed sequences.
1095

1096 We employ multiple complementary metrics to assess different aspects of sequence design:

- 1097 • **Sequence Naturalness** We utilize perplexity scores from ProGen2 (Nijkamp et al., 2023), an
1098 autoregressive protein language model, to quantify how well the generated sequences align with
1099 natural sequence distributions. Lower perplexity indicates sequences that better match patterns
1100 observed in natural proteins.
- 1101 • **Structural Stability** For structure-based evaluation, we use single-sequence folding model ESM-
1102 Fold (Lin et al., 2023b) to predict the structure of the generated sequences, and then measure the
1103 structural quality by pLDDT as the proxy of structural stability of the sequence.
- 1104 • **Structural Properties** We evaluate structural diversity and novelty using the same protocols es-
1105 tablished in backbone design evaluation, ensuring a comprehensive assessment of the structural
1106 characteristics of generated sequences.
1107

1108 **[Datasets]** For the training dataset, UniRef50 (Suzek et al., 2015) is the commonly used dataset
1109 for training protein sequence generative models and language models. Similar to backbone design,
1110 to conduct a comprehensive performance analysis of protein sequence generation, we compare the
1111 models’ performance against the distribution of real sequence data. Specifically, we randomly sam-
1112 pled 50 protein sequences from UniRef50 to serve as references for the data distribution.
1113

1114 **[Model implementations]**

1115 To ensure comprehensive evaluation, we test each method’s ability to perform unconditional
1116 monomer generation across diverse protein sizes. We follow the official repository and instruc-
1117 tions for inference. The generation process is constrained only by specified target lengths, which we
1118 set at 100, 200, 300, 400, and 500 residues.
1119

1120 B.1.4 STRUCTURE AND SEQUENCE CO-DESIGN

1121 **[Task Definition]** Protein structure-sequence co-design represents an advanced challenge in protein
1122 engineering that involves the simultaneous optimization of both backbone structure and amino acid
1123 sequence. This integrated approach aims to achieve desired properties or functions while maintain-
1124 ing structural stability and sequence compatibility. Unlike isolated sequence or structure design,
1125 co-design explores a significantly larger solution space, making it both more challenging and poten-
1126 tially more powerful for creating novel functional proteins.

1127 **[Evaluation Metrics]** The evaluation of co-designed proteins requires a comprehensive framework
1128 that addresses both structural and sequence aspects simultaneously. This dual consideration is essen-
1129 tial because success in either domain alone is insufficient - the designed sequence must be compat-
1130 ible with its intended structure, and both must contribute to the desired functional properties. The
1131 interdependence of sequence and structure necessitates metrics that can capture this relationship
1132 effectively.
1133

1133 We implement a multi-faceted evaluation approach that combines metrics from both sequence and
structure design domains:

- 1134 • **Quality** We use a similar self-consistency-based designability in backbone design for the co-
1135 design task, but with a key difference. The quality for simultaneously co-generated structure and
1136 sequence is about structure-sequence compatibility by measuring how well the designed sequence
1137 can fold into the corresponding designed structure, using scTM and scRMSD, whereas backbone
1138 design models require an additional inverse folding model, such as ProteinMPNN, to design the
1139 sequence.
- 1140 • **Novelty** Similar to backbone design, we measure the structural novelty compared to known pro-
1141 teins, ensuring that designs represent meaningful additions to the protein design space while main-
1142 taining realistic properties.
- 1143 • **Diversity** Similar to backbone design, we measure the structural diversity by maximum pair-wise
1144 TM-scores and the number of distinct structural clusters using Foldseek.

1145 **[Datasets]** High-resolution protein structures from the Protein Data Bank (PDB) are the commonly
1146 used datasets for this task, with careful consideration given to remove redundancy.

1147 **[Model implementations]** To ensure comprehensive evaluation, we test each method’s ability to
1148 perform unconditional monomer generation across diverse protein sizes. We follow the official
1149 repository and instructions for inference. The generation process is constrained only by specified
1150 target lengths, which we set at 100, 200, 300, 400, and 500 residues. This range allows us to assess
1151 method performance across both small proteins and larger, more complex structures.

1152 B.1.5 MOTIF SCAFFOLDING

1153 **[Task Definition]** Motif scaffolding represents a specialized challenge in protein design that
1154 focuses on creating protein structures incorporating specific functional motifs or binding sites.
1155 The objective is to engineer a stable protein framework that precisely positions the desired motif
1156 while maintaining its functional geometry. This task is crucial for developing proteins with targeted
1157 functionalities, including enzyme design, therapeutic proteins, and biomolecular recognition
1158 systems.

1159 **[Evaluation Metrics]** Evaluating motif scaffolding designs requires a careful balance between
1160 maintaining the precise geometry of the functional motif and ensuring the overall stability of the
1161 scaffold structure. The assessment must consider both the structural accuracy of the motif placement
1162 and the broader protein context that supports it, making this a multi-scale evaluation challenge.

1163 We measure motif scaffolding in terms of both motif accuracy and overall designability. For motif
1164 accuracy, we calculate RMSD between the input motif structure and the corresponding region of the
1165 designed protein to assess whether the motif structure is preserved ($\text{motifRMSD} < 1.0$). As for the
1166 overall designability, we use scTM score > 0.8 as being designable. We have accordingly elaborated
1167 on motif-scaffolding evaluation in the appendix.

1168 **[Datasets]** Datasets typically include libraries of known functional motifs (e.g., catalytic sites,
1169 binding interfaces) and diverse scaffold structures that can potentially accommodate these motifs.
1170 The Protein Data Bank is a primary source, but curated datasets of functional sites like the Catalytic
1171 Site Atlas are also valuable.

1172 **[Related benchmarks]** Enzyme Design Challenge provides relevant test cases. However, given the
1173 specificity of motif scaffolding tasks, benchmarks often need to be tailored to the particular class of
1174 motifs or functions being targeted. Currently, there exists no comprehensive benchmark for this task
1175 in the field. A widely used benchmark containing 17 (25) motif-scaffolding problems was used in
1176 RFDiffusion (Watson et al., 2023b).

1177 **[Evaluation Metrics]** Following Yim et al. (2024), we implement several key metrics.

- 1178 • **Motif Accuracy** We measure the structural retention of motif placement using RMSD calcula-
1179 tions, focusing on the geometric alignment of critical functional elements.
- 1180 • **Overall Designability** We assess the overall stability and structural integrity of the designed pro-
1181 tein framework using metrics using self-consistency TM Score.

1182 **[Model implementations]** Structure-based models (FrameFlow, RFDiffusion), sequence-based
1183 models (DPLM, EvoDiff), and multimodal models (ESM3) require different ways to take as in-

1188 Figure 3: Sequence-based, structure-based, and co-generation evaluation pipeline of motif-
 1189 scaffolding.

| sequence-based | |
|------------------|---|
| prediction | seq _{pred} : ✓ struct _{pred} : ✗ |
| motif-preserving | $\text{RMSD}(\text{ESMFold}(\text{seq}_{\text{pred}})[\text{motif}], \text{struct}_{\text{native}}[\text{motif}]) < 1.0$ |
| designability | $\text{pLDDT}(\text{ESMFold}(\text{seq}_{\text{pred}})) > 70$ |
| structure-based | |
| prediction | seq _{pred} : ✗ struct _{pred} : ✓ |
| motif-preserving | $\text{RMSD}(\text{ESMFold}(\text{PMPNN}(\text{struct}_{\text{pred}}))[\text{motif}], \text{struct}_{\text{native}}[\text{motif}]) < 1.0$ |
| designability | $\text{TMScore}(\text{ESMFold}(\text{PMPNN}(\text{struct}_{\text{pred}})), \text{struct}_{\text{pred}}) > 0.8$ |
| co-generation | |
| prediction | seq _{pred} : ✓ struct _{pred} : ✓ |
| motif-preserving | $\text{RMSD}(\text{ESMFold}(\text{seq}_{\text{pred}})[\text{motif}], \text{struct}_{\text{native}}[\text{motif}]) < 1.0$ |
| designability | $\text{TMScore}(\text{ESMFold}(\text{seq}_{\text{pred}}), \text{struct}_{\text{pred}}) > 0.8$ |

1205 put the motif information and generate the scaffolds. For example, structure-based methods require
 1206 an extra sequence design model to predict sequences of the designed proteins, while sequence-based
 1207 methods cannot directly read motif structure and also require an extra folding model to predict the
 1208 structure of the designed proteins. Multimodal approaches, on the other hand, can read and predict
 1209 structure and sequence simultaneously by themselves. Hence, comparing them in completely identical
 1210 settings is challenging, and we resort to slightly different criteria to evaluate these approaches.

1211 We focus on two aspects to assess the success of motif scaffolding: overall designability and motif-
 1212 preservation. The overall illustration is shown in Figure 3. Specifically, (1) For the sequence-based
 1213 method, we only take the generated sequence and utilize ESMFold to obtain the predicted structure,
 1214 and the pLDDT score provided by ESMFold is used to assess overall quality. (2) For the structure-
 1215 based method, we only take the generated structure and then leverage ProteinMPNN to predict the
 1216 sequence, followed by ESMFold to predict the structure, where overall quality is assessed by scTM.
 1217 (3) For the co-generation method, we take both the generated structure and sequence and predict
 1218 the structure given the generated sequence with ESMFold, where scTM is calculated between the
 1219 generated structure and ESMFold predicted structure to evaluate overall quality. Considering that
 1220 the ground truth motif structure is given, we only utilize the ESMFold predicted structure to calculate
 1221 motif-RMSD.

1223 B.1.6 ANTIBODY DESIGN

1225 **[Task Definition]** The goal of antibody design is to generate antibodies that can specifically bind
 1226 to a given antigen. Since the Complementarity-Determining Regions (CDRs) of antibodies are
 1227 highly variable and primarily responsible for antigen binding, antibody design could be simplified
 1228 to the design of CDR regions and further reduced to the design of the third CDR in heavy chain
 1229 (CDR-H3). Given the crucial role that protein structure plays in interactions, antibody design
 1230 usually involves the simultaneous design of the sequence and the structure when binding to the
 1231 antigen.

1232 **[Evaluation Metrics]** As mentioned in the main text, antibody design can ultimately be simplified
 1233 to the design of CDR-H3. Therefore, in this study, we evaluate the performance of different anti-
 1234 body design methods by evaluating the CDR-H3 sequences generated by these methods. Given the
 1235 primary objective of this study is to assess the relative performance of various design models rather
 1236 than the in vivo/vitro functionality of the antibodies they generate, we opted to directly evaluate the
 1237 designed antibodies using their predicted structures. This approach is grounded in several consid-
 1238 erations: firstly, it ensures a clear focus on evaluating the design methodology itself, independent
 1239 of experimental constraints. Secondly, the significant time and resources required for extensive ex-
 1240 perimental validations, as well as the limitations of methods that can accurately simulate the real
 1241 binding structure of antibodies, render in vivo/vitro assessments impractical. Direct evaluation of
 the designed structures presents a feasible and efficient strategy that aligns with the study’s goals

1242 and resource constraints while still providing valuable theoretical benchmarks for subsequent exper-
1243 imental investigations.

1244 For methods capable of generating multiple antibodies for the same antigen, we generated 64
1245 CDR-H3 sequences per antigen using each method and calculated the average performance across
1246 these different generated samples. Additionally, we also calculated the standard deviation of the
1247 performance among different samples generated for a single antigen.
1248

1249 As a highly goal-oriented functional protein design task, the evaluation of antibody design is
1250 straightforward, namely the **Functionality** (binding capability to the target antigen) and **Specificity**
1251 of the designed antibody. Additionally, the **Rationality** of the designed antibodies sequence
1252 and structure needs to be evaluated for filtering out invalid designs. However, it remains a
1253 challenging task to accurately simulate the performance of antibodies in real wet-lab experiments,
1254 including functionality and specificity, using computational methods, and there is a lack of reliable
1255 approaches. Therefore, we focus on evaluating antibody design models. Superior models can often
1256 provide a better understanding of interactions between antibodies and antigens, potentially leading
1257 to the production of improved antibodies. Although both the evaluation of design models and
1258 antibodies involve assessing antibodies, their approaches differ. The former directly evaluates the
1259 structures and sequences generated by the models without modifications, whereas the latter focuses
1260 on the actual performance of antibodies in experiments, meaning that their structures may change
1261 and differ from the design. Existing studies also evaluate the **Accuracy** of designed antibodies
1262 by measuring their similarity to natural antibodies as natural ones are confirmed to be effective.
1263 However, using accuracy as an evaluation metric is inadequate in many cases, we demonstrate the
1264 misleadingness of AAR and RMSD in 2.1.6.

1265 **Accuracy:**

- 1266 • **AAR:** AAR is the accuracy evaluation of generated sequences compared to reference/natural se-
1267 quences. For the calculation of AAR (Amino Acid Recovery Rate), similar to existing work,
1268 we calculated the number of residues in the generated CDR-H3 sequences that match the natural
1269 antibody.
1270
- 1271 • **RMSD:** RMSD is the consistency evaluation of generated structures compared to reference/natural
1272 structures. In the calculation of RMSD (Root Mean Square Deviation), we measured the RMSD
1273 of the generated and natural antibodies in the CA coordinates of the CDR-H3 region. For methods
1274 other than dyMEAN, since their task setting provides the true binding pose of the antibody FR
1275 region and antigen, there is no need to align the generated structure with the natural structure
1276 when calculating RMSD. For dyMEAN, we aligned the 2 FR residues at each end of CDR-H3
1277 with the corresponding residues in the natural antibody, applied the obtained transformation to
1278 CDR-H3, and then calculated the RMSD.
- 1279 • **TM-score:** TM-score is also the consistency evaluation of generated structures compared to refer-
1280 ence/natural structures. We calculated the TM-score only for the CDR-H3 region. To this end, we
1281 saved the generated CDR-H3 part as a .pdb file and used TMalign (Zhang & Skolnick, 2005) to
1282 calculate the TM-score between the generated CDR-H3 and the natural CDR-H3.

1283 **Functionality:**

- 1284 • **Binding Energy:** Binding Energy indicates the strength of antibody-antigen binding with the gener-
1285 ated structures and we use Rosetta to calculate the Binding Energy. The calculation of binding
1286 energy requires the all-atom structure of the protein, while most methods only generate the back-
1287 bone atom structure. Therefore, we first used Rosetta to pack the missing side-chain atoms. Sub-
1288 sequently, we optimized the side-chains in the CDR-H3 region using Rosetta minimization while
1289 keeping the backbone structure unchanged to ensure that the CDR-H3 generated by the model
1290 reaches the minimum energy state in the binding environment with the antigen. During minimiza-
1291 tion, we set the step to 100 (we tried using more steps and repeats, although the energy did further
1292 decrease, the reduction was very limited and much smaller than the energy difference between
1293 different methods; however, the time consumption significantly increased). After minimization,
1294 we calculated the energy on the all-atom structure. Finally, we used the InterfaceAnalyzer
1295 in Rosetta to calculate the binding energy between CDR-H3 and the antigen.

Specificity:

1296 • SeqSim: We use SeqSim to detect the mode collapse in sequence generation (or sequence speci-
 1297 ficity towards different antigens), which indicates that the generated antibodies lost the specificity
 1298 for specific antigens. SeqSim is defined as the average similarity between any sequence pairs
 1299 among the generated sequences. First, we introduce the definition and implementation of similar-
 1300 ity. The similarity between two sequences is defined as the percentage of matched amino acids
 1301 over the aligned length after alignment (thus, this metric is affected by the length gap between
 1302 the two sequences). Given that our goal is to calculate the number of matches rather than the
 1303 matching score and that the two ends of CDR-H3 are fixed to FR3 and FR4, we need an align-
 1304 ment method that: (1) assigns a score of 1 for matches, and 0 for gaps and mismatches; (2) does
 1305 not introduce gaps at the two ends of CDR-H3. We used the PairwiseAligner in Biopython
 1306 (Cock et al., 2009) for sequence alignment, setting match_score to 1, all other scores to 0, and
 1307 the end_gap_score to *-inf* so that the alignment process meets our requirements. For methods
 1308 that generate only one antibody per antigen, we directly calculate the average SeqSim among the
 1309 55 generated CDR-H3 sequences as SeqSim-outer. For methods that generate multiple antibod-
 1310 ies, we calculate the average SeqSim between two sets of sequences generated for two antigens
 1311 as SeqSim-outer and also calculate the average SeqSim within each set as SeqSim-inner. The
 1312 formulas for calculating SeqSim-outer and SeqSim-inner are as follows:

$$1313 \text{SeqSim-outer} = \frac{1}{N * (N - 1) * M^2} \sum_{i=1}^N \sum_{j=1|j \neq i}^N \sum_{x=1}^M \sum_{y=1}^M \text{SeqSim}(s_i^x, s_j^y), \quad (1)$$

$$1316 \text{SeqSim-inner} = \frac{1}{N * M * (M - 1)} \sum_{i=1}^N \sum_{x=1}^M \sum_{y=1|y \neq x}^M \text{SeqSim}(s_i^x, s_i^y), \quad (2)$$

1319 where N denotes the number of antigens in the test set ($N=55$ in this study), M denotes the
 1320 number of samples generated for each antigen ($M=64$ in this study), and s_i^x represents the x -th
 1321 CDR-H3 sequence generated for the i -th antigen.

1322 • PHR: PHR is the proportion of hydrophobic residues in the generated CDR-H3 sequences, can
 1323 also reflect the lack of specificity, as the binding caused by the interactions generated by these
 1324 residues is generally considered to lack antigen specificity. Although both PHR and SeqSim are
 1325 used to represent the specificity of antibody design methods, they focus on different aspects. Thus,
 1326 the same method may exhibit different tendencies in these two metrics (SeqSim can be understood
 1327 as an evaluation of the method’s specificity, while PHR is an evaluation of the specificity of the
 1328 generated antibodies. When SeqSim performs poorly, the performance of PHR is of limited sig-
 1329 nificance). For example, AbDPO achieves high SeqSim-outer but does not perform well in PHR.
 1330 This indicates that AbDPO can specifically design antibodies for different antigens, but these an-
 1331 tibodies contain many hydrophobic residues, leading to potential nonspecific interactions with
 1332 multiple proteins.

1333 Rationality:

1334 • CN-Score: CN-Score is the evaluation of the rationality of the structure by scoring the distribution
 1335 of generated peptide bond length. To evaluate the consistency of the peptide bond length of
 1336 generated antibodies with that of natural antibodies, we fit a Kernel Density Estimation (KDE)
 1337 function using the length of peptide bonds found within the CDR-H3 regions of natural antibodies.
 1338 The density of the generated peptide bond length, CN-Score, is used to represent the consistency.
 1339 For generated peptide bonds shorter than the minimum natural peptide bond length or longer than
 1340 the maximum, the density is defined as 0. The final CN-Score for a generated antibody is defined
 1341 as the average density of the lengths of all its peptide bonds. It is important to note that the length
 1342 variation of peptide bonds is very small, which leads to a very narrow distribution of natural
 1343 peptide bond lengths. When the generated peptide bond length deviates slightly from the average
 1344 length (1.3310), its density in the KDE function will sharply decrease, which explains why all
 1345 methods show a significant difference in CN-Score compared to natural antibodies.

1346 • Clashes: Clashes is the assessment of the potential clashes. Although atomic clashes within pro-
 1347 teins mainly occur between the side chains, most methods do not generate the side chains of
 1348 residues. Using packing methods to complete side chains can always find a side-chain confor-
 1349 mation with the fewest clashes through extensive searching. Therefore, we instead evaluate the
 potential clash level in the generated structures rather than the specific number of clashes. To do

1350 this, we calculate the CA distance between two residues; when the CA-CA distance between two
1351 residues not connected by a covalent bond is less than the minimum CA-CA distance commonly
1352 found in covalently bonded residues (3.6574, derived from the CA-CA distance statistics in the
1353 CDR-H3 region of the RAbD dataset), we consider these two residues to have potential clashes.
1354 We then calculate the number of residue pairs with distances below this threshold to measure the
1355 clash level in the generated structures. The difference between Clashes-inner and Clashes-outer
1356 is: Clashes-inner measures the clash level within the generated CDR-H3 structure, while Clashes-
1357 outer measures the clash level between the generated CDR-H3 structure and other components,
1358 including the antigen, the heavy chain FR region, and the light chain of the antibody.

- 1359 • SeqNat: [SeqNat, Sequence naturalness, is the evaluation of the rationality of the generated se-](#)
1360 [quence.](#) To measure how close the designed CDR-H3 sequences are to natural sequences, we used
1361 the pLL predicted by the AntiBERTy model. We input the entire heavy chain sequence into the
1362 model, which means that AntiBERTy makes predictions based on the entire heavy chain of the
1363 antibody, but unlike the standard procedure in AntiBERTy, the pLL calculation area is only within
1364 the CDR-H3 region (the standard procedure calculates pLL over the entire input sequence).
- 1365 • Total Energy: [Total Energy is the evaluation of the joint rationality of the generated sequence](#)
1366 [and structure from the perspective of physical energy.](#) Before calculating the total energy, we
1367 performed the same energy optimization process on the designed CDR-H3 regions as described
1368 in the Functionality section. We then used Rosetta's full atom score function with the default
1369 weights from REF15 (Alford et al., 2017) to calculate the total energy of each residue in the CDR-
1370 H3 region. The Total Energy of the CDR-H3 region is defined as the sum of the total energy of all
1371 its residues.
- 1372 • scRMSD: [We use scRMSD to evaluate the model's ability of structural modeling by calculating](#)
1373 [the difference between the designed structure and the simulated structure.](#) In this metric, [we used](#)
1374 [a two-stage method to predict the structure of the generated sequences. In the first stage, we used](#)
1375 [IgFold to predict the structure based on the sequence pair of the antibody's light and heavy chains](#)
1376 [\(although the region we evaluate only exists in the heavy chain, and IgFold also supports single-](#)
1377 [chain input, we found that inputting two chains results in higher accuracy\).](#) The real structure
1378 of the non-CDR-H3 regions of the antibody was also provided as a template to obtain the initial
1379 predicted structure. We then used the Kabsch algorithm to align the non-CDR-H3 regions of the
1380 heavy chain with the real structure and applied the resulting transformation to the predicted CDR-
1381 H3 structure. This aligns the predicted CDR-H3 structure to its original complex. At this point, the
1382 CA-RMSD between the predicted CDR-H3 structure and the real structure in the RAbD dataset
1383 is 1.95. The structure predicted by IgFold is unrelated to the antigen, and since the antibody
1384 undergoes conformational changes in the binding interface after binding with the antigen, we
1385 used Rosetta to relax the predicted CDR-H3 in the presence of the antigen [in the second stage.](#)
1386 The relaxation involves changes in both the backbone and side-chain structures. Specifically, we
1387 repeated relaxation runs five times for each structure predicted by IgFold, with 200 steps each
1388 time, and selected the structure with the lowest energy as the final predicted structure. At this
1389 stage, the CA-RMSD with the real structure decreased to 1.77. We then calculated the RMSD of
1390 the CA coordinates between the predicted structure and the backbone CA coordinates generated
1391 by the model, which is referred to as scRMSD.

1390 **[Datasets]** The Structural Antibody Database (SAbDab Dunbar et al. (2013)) is the commonly used
1391 dataset for antibody design. It contains structural data of the antibody-antigen complex, but the data
1392 size is limited and contains numerous redundancies. [Although SAbDab's official statistics indicate](#)
1393 [that the database includes over 8,000 entries of complexes containing antigens, only more than 3,000](#)
1394 [entries remain after deduplication.](#) Furthermore, researchers typically cluster the SAbDab data
1395 based on the sequence identity of CDR-H3, with a clustering threshold generally set at 40% iden-
1396 tity. Subsequently, within different clusters, the data is divided into training, validation, and test sets.

1398 **[Model Implementations]** We retrained all the methods with unified training data and the official
1399 training config for a fair comparison and evaluated the methods with unified test data.

1401 **Training data:**

1402 To build the unified training data, we use antibody-antigen complex structural data from the
1403 SAbDab dataset under the IMGT scheme (Lefranc et al., 2009) as the training dataset. We collected
antigen-antibody complexes with both heavy and light chains and protein antigens. We then

1404 discarded duplicate data with the same CDR-L3 and CDR-H3 sequence. The remaining complexes
1405 are used to cluster via MMseqs2 (Steinegger & Söding, 2017) with 40% sequence similarity as the
1406 threshold based on the CDR-H3 sequence of each complex. Finally, we select the clusters that do
1407 not contain complexes in the RAbD dataset and split the complexes into training and validation sets
1408 with a ratio of 9:1 (1786 and 193 complexes respectively).

1409 **Test data:**

1410 To build the unified test data, we extracted 55 antibody-antigen complexes from the RAbD dataset.
1411 The original RAbD dataset contains 60 antibody-antigen complexes. In this study, we hope that
1412 the evaluation of antibody design methods is based on antibodies that contain both light and heavy
1413 chains, and simultaneously the antigen contains at least one protein chain. In practice, **2ghw** and
1414 **3uzq** lack light chains, while **3h3b** lack heavy chains. **5d96** is excluded because of the incorrect
1415 chain ID information in rabd_summary.jsonl⁴, where heavy chain *J* and light chain *I* do not bind to
1416 antigen chain *A*. **4etq** is excluded as HERN reported an error when running for this complex.
1417

1418 **Model:**

1419 All the models are retrained with their default training config. It should be noted that [**dyMEAN-**
1420 **FixFR**] is not an official variant of dyMEAN, and we implemented this variant for a fair comparison
1421 with other methods. Unlike other methods, which are designed to accept the true structure of
1422 the antibody-antigen complex and generate the missing CDR-H3 region, dyMEAN is set up to
1423 accept only the structure of the antigen and the sequence of the non-CDR-H3 regions of the
1424 antibody. Therefore, the model needs to both generate the CDR-H3 region and predict the overall
1425 structure of the antibody as well as the binding pose between the antibody and antigen. Incorrect
1426 pose estimation can severely affect the interactions between CDR-H3 and the antigen, making a
1427 direct comparison between dyMEAN and other methods unfair. To compare dyMEAN with other
1428 methods more fairly, we made some modifications to dyMEAN by providing the true structure of
1429 the non-CDR-H3 regions of the antibody and the binding pose, aligning dyMEAN with the other
1430 methods. In dyMEAN-FixFR, we also used Rosetta (Alford et al., 2017) to repack the side chains,
1431 consistent with other methods, to avoid the influence of the side chains generated by dyMEAN
1432 on the evaluation results. Additionally, we introduced some randomness in the initialization of
1433 the structure, which allows dyMEAN-FixFR to generate multiple different antibodies for the same
1434 antigen.

1435 **[Extended Explanations and Discussion on Model Performance]**

1436 **Specificity:**

- 1437
- 1438 • In **SeqSim-outer**, we noted that MEAN and dyMEAN generated highly similar sequences for dif-
1439 ferent antigens (the maximum **SeqSim-outer** in our test set was 0.79, indicating that all antibody
1440 differences came only from length variations). This suggests that their excellent AAR might stem
1441 from learning high-frequency patterns in antibody sequences, generating antibodies according to
1442 these patterns for different antigens. In contrast, DiffAb and AbDPO performed the best.
- 1443 • For methods that can generate different antibodies for the same antigen, we also measured the
1444 sequence similarity among different antibodies generated for the same antigen (**SeqSim-inner**).
1445 We expect antibodies generated for the same antigen to be more similar. In this aspect, dyMEAN-
1446 FixFR and AbDPO performed the best. However, the 0.96 **SeqSim-inner** of dyMEAN-FixFR
1447 indicates that despite introducing randomness during model initialization, the final sequence gen-
1448 eration showed almost no differences. Additionally, DiffAb, which performed best in **SeqSim-**
1449 **outer**, generated less similar antibodies for the same antigen, suggesting possible underfitting in
1450 sequence generation. Considering both types of **SeqSim**, AbDPO achieved the best performance.
- 1451 • In **PHR**, HERN and dyMEAN performed the best, but overall, almost all methods performed bet-
1452 ter than natural antibodies. Only AbDPO generated an excessive number of hydrophobic residues,
1453 reducing specificity. However, its variant, AbDPO++, controlled **PHR** well, closely matching nat-
1454 ural antibodies among all methods.

1455 **Rationality:**

1456 ⁴[https://github.com/THUNLP-MT/MEAN/blob/main/summaries/rabd_summary.](https://github.com/THUNLP-MT/MEAN/blob/main/summaries/rabd_summary.jsonl)
1457 [jsonl](https://github.com/THUNLP-MT/MEAN/blob/main/summaries/rabd_summary.jsonl)

- In structural rationality, we focused on the score for peptide bond lengths conforming to the natural peptide bonds length distribution (**CN-score**), the number of potential internal clashes in the generated structure (**Clashes-inner**), and the clashes between the generated structure and other parts (**Clashes-outer**). It was evident that irrational structures were prevalent in generated antibodies, but overall, diffusion-based methods performed better. AbDPO++ and DiffAb achieved the best performance among all methods. HERN and MEAN/dyMEAN exhibited different tendencies in **Clashes-inner/outer**, corresponding to our observations of the generated samples. HERN tends to generate large CDR-H3 structures, leading to fewer internal clashes but more clashes with the antigen, whereas MEAN/dyMEAN tends to generate smaller CDR-H3 structures.
- In sequence rationality, we used the inverse perplexity of AntiBERTy (Ruffolo et al., 2021) to represent sequence naturalness, **SeqNat**, showing that HERN performed the best, possibly due to HERN being the only auto-regressive model. AbDPO++ achieved the second-best performance and was closest to natural antibodies.
- In the joint evaluation of structure and sequence, we mainly focused on the consistency between the generated structure and sequence from two perspectives: physical energy and structure prediction. In terms of physical energy, we calculated the total energy of the generated CDR-H3s (**Total Energy**), which would be severely affected by the clashes caused by sidechains and thus reflect the irrationality between the generated structure and sequence. In this energy-related metric, AbDPO and AbDPO++ performed best among all methods. From the perspective of structure prediction, we used IgFold (Ruffolo et al., 2023) to predict the structure of the generated sequence, performed a post-optimization with the antigen as the condition, and calculated the CA-RMSD between the predicted structure and the generated structure (**scRMSD**). dyMEAN and dyMEAN-FixFR performed best in **scRMSD**. Although these two metrics both reflect the consistency between sequence and structure, they focus on different aspects. Moreover, both energy calculations and structure predictions have inherent errors, so the performance of different methods may not be consistent across these two metrics.

B.2 PROTEIN CONFORMATION PREDICTION

B.2.1 PROTEIN FOLDING: SINGLE-STATE PREDICTION

[Task Definition] Protein folding task predicts the three-dimensional (3D) structure of a protein based on its sequence. Folding models such as AlphaFold2 (Jumper et al., 2021) have achieved unprecedented accuracy in predicting protein structures at scale, complementing experimental characterizations and driving advancements in biology and drug discovery (Varadi et al., 2022). From a modeling perspective, sequence-to-structure prediction is a critical measure of a model’s understanding of these two modalities. Furthermore, the ability to translate sequences into structures forms the foundation for recent progress in protein conformation prediction (Jing et al., 2024; Zheng et al., 2024; Wang et al., 2024c). As such, we recognize the necessity of including protein folding in this benchmark, viewing it as a specific instance of protein conformation prediction for a single conformational state.

[Evaluation Metrics] The primary goal of evaluating protein folding models is to assess their *accuracy* in predicting 3D structures of unseen proteins. This is done by comparing the predicted structures to reference structures, such as experimentally determined ones available in the Protein Data Bank (PDB). To ensure an unbiased evaluation, time-based splits are commonly employed, using recently deposited structures of previously unseen proteins for benchmarking (cas, 2022; Robin et al., 2021). Beyond accuracy, the ability to predict protein structures with minimal structural violations provides a reference-free measure of a model’s capability to generate high-quality protein conformations. Unlike the design tasks discussed earlier, structural diversity is not a focus in this evaluation. Detailed implementations are provided below:

- **Accuracy:** Structural accuracy is measured by the structural similarity with reference structures. Specifically, *global* similarity metrics including TM-score, RMSD and global distance test (GDT) are calculated using `TMscore` Zhang & Skolnick (2004) obtained from <https://zhanggroup.org/TM-score/>. We use `-seq` option to align sequences before structural alignment. Local distance difference test (IDDT) is an alignment-free method to compare *local* structural similarity. We calculate the value using the original implementation (Mariani et al., 2013) from <https://swissmodel.expasy.org/lddt/downloads/>.

1512 • **Quality:** The structural quality of generated conformations are assessed by CA clash % and
1513 PepBond-break %:

1514 – CA clash % is the rate of potential clashes based on the positions of alpha-carbon atoms. A
1515 *clash* is determined if the distance between a pair of alpha carbon atoms is less than 3.0 Å,
1516 similar to Lu et al. (2024). And CA clash % is calculated as

$$1517 \text{CA clash \%} = \frac{\text{number of residues with clashes}}{\text{sequence length}} \times 100\%.$$

1518 – PepBond break % evaluates the potential peptide bond (C-N) break between connecting
1519 residues, providing a more rigorous metric about inter-residue disconnection than CA level
1520 metrics used in Lu et al. (2024). We use a maximum peptide length threshold of 1.4 Å to
1521 determine a chain break, as suggested by the BioPython implementation⁵. Similarly, PepBond
1522 break % is calculated as

$$1523 \text{PepBond break \%} = \frac{\text{number of C-N bond break}}{\text{sequence length} - 1} \times 100\%.$$

1524 **[Datasets]** The folding models included in this benchmark are those that serve as base models for
1525 protein conformational predictions and were established prior to 2022. We use CAMEO2022 from
1526 Jing et al. (2023) for evaluation, which consists of 183 short-to-mid-length single protein chains (<
1527 750 amino acids) from the targets of CAMEO (a continuous benchmarking initiative for structure
1528 prediction of newly deposited protein structures) between Aug 1 and Oct 31, 2022. CAMEO2022
1529 consists of 183 single protein chains collected from CAMEO targets between August and October
1530 2022, with sequence lengths of less than 750 amino acids, following Jing et al. (2023). Protein
1531 sequences and structures were extracted from the mmCIF files available at the RCSB Protein Data
1532 Bank (<https://www.rcsb.org/>, Berman et al. (2000)). One of the proteins (PDB ID: 8AHP, chain A)
1533 has since been superseded by a new PDB entry 8QCW and we have replaced this chain with the
1534 updated record.

1535 **[Model Implementations]** Several folding models, including AlphaFold2, OpenFold,
1536 RoseTTAFold2, use Multiple Sequence Alignment (MSA) as sequence input. We standard-
1537 ize MSA curation using the querying pipeline and the online server provided by ColabFold (Mirdita
1538 et al., 2022). Templates are not provided in model inference. Additional model implementation
1539 details for each model are as follows:

1540 • AlphaFold2 (Jumper et al., 2021): We used the ColabFold implementation Mirdita et al. (2022)
1541 for AlphaFold2 inference. All five models (with pTM) were used to predict five candidate struc-
1542 tures, and the structure with the highest pLDDT confidence score was selected for performance
1543 evaluation. All models were run with default settings.

1544 • OpenFold (Ahdritz et al., 2022): We used `openfold v2.0.0` for inference
1545 with their pretrained OpenFold weights (with pTM). Since only one checkpoint
1546 (`finetuning_no_tmpl_ptm_1`) corresponding to the model configuration `model_3_ptm`
1547 is available, we generated three structures using three random seeds and made a total of
1548 5 predictions. The structure with the highest pLDDT score was selected for performance
1549 evaluation.

1550 • ESMFold (Lin et al., 2023a): We use the public ESM repository for inference with the model
1551 `esm.pretrained.esmfold_v1`. Since EMSFold predictions are deterministic, we generated
1552 only one structure per protein for performance evaluation.

1553 • RoseTTAFold2 (Baek et al., 2023): We follow their official repository and instructions for infer-
1554 ence. Only one structure per protein was predicted for performance evaluation.

1555 • EigenFold (Jing et al., 2023): We follow the official repository, weights, and the setups provided
1556 by the authors for inference. In the *protein folding* task, we sampled 5 structures for each protein
1557 and selected the one with the highest ELBO estimation for performance evaluation. Because
1558 EigenFold can not predict sequences containing unknown amino acids (labeled 'X'), we removed
1559 the 'X' in the input sequences, as done in the original implementation.

1560 ⁵https://biopython.org/docs/dev/api/Bio.PDB.internal_coords.html#Bio.PDB.internal_coords.IC_Chain

1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619

[Extended Explanations and Discussion on Model Performance]

Our benchmarking results (Table 7 align with previous reports (Jing et al., 2023), showing that MSA-based folding model generally outperforms protein-language-model-based folding model. EigenFold (Jing et al., 2023), one of the first diffusion generative models for both protein folding and conformation prediction, shows relatively weaker performance on the folding task. Its performance could be limited by several design factors: it is built on OmegaFold Wu et al. (2022), uses a coarse-grained representation with only alpha carbons, and has a small model size of 572K trainable parameters.

B.2.2 MULTIPLE-STATE PREDICTION

[Task Definition] Multiple-state prediction builds upon single-state prediction by aiming to accurately generate two or more distinct conformational states of a protein. These states are typically associated with functional conformational changes, such as those induced by ligand binding, or metastable states observed during molecular dynamics simulations. The ability to predict these "alternative" conformations, in addition to the folded structure, offers valuable insights into a model's capability to generate plausible stable conformational states. This serves as an essential first step toward understanding protein conformational dynamics.

[Evaluation Metrics] The **accuracy** and **quality** metrics for multiple-state prediction are naturally derived from those used in single-state prediction, with some modifications. Unlike single-state prediction, multiple-state prediction involves sampling an ensemble of conformations from the model. Given a fixed sample size, the accuracy of recovering one state can be evaluated as the best accuracy among all samples compared to the reference structure. For direct model comparison, a single accuracy score is preferred to represent the average performance across the recovery of different states. Additionally, transitioning from folding to conformation generation introduces the need to evaluate the **diversity** of the generated samples, reflecting the model's ability to capture a range of plausible conformational states. Implementation details are as follows:

- **Accuracy:** The accuracy of predicting a conformational state is determined by the best structural similarity among the samples to the reference structure, measured by TM-score (for **Apo-holo** with multiple proteins) or RMSD (for **BPTI** with one protein). Use RMSD as an example:

$$\text{Accuracy of state } k = \min_{\mathbf{x}_i \in \text{samples}} \text{RMSD}(\mathbf{x}_i, \mathbf{x}_k^{\text{ref}})$$

we then calculate the average accuracy across states as in Jing et al. (2023), referred as "ensemble accuracy":

$$\text{Ensemble RMSD} = \frac{1}{K} \sum_{k \in K \text{ states}} \text{Accuracy of state } k$$

- **Diversity:** Diversity is evaluated by the average pairwise structural similarity among the generated samples for a protein, measured using TM-score or RMSD. To reduce computation time, we randomly sample 100 pairs of structures for estimation.
- **Quality:** The structural quality is evaluated using CA clash and PepBond-break, see single-state prediction for details.

[Datasets] We benchmark the models on two datasets reflect common scenarios in the study of protein conformational changes: **apo-holo** captures the conformational changes related to specific protein function (i.e., ligand-binding processes) (Saldaño et al., 2022) and BPTI captures the metastable states discovered from long-time MD simulations (Shaw et al., 2010). Specifically:

- **Apo-holo** consists of 91 single chain proteins curated by Saldaño et al. (2022), each featuring a pair of experimentally determined conformations: *apo* (unbound) and *holo* (bound), representing a two-state prediction task related to ligand-binding. The protein sequences and the structures of both *apo* and *holo* conformations were extracted using the same pipeline as in CAMEO2022. Consistent with Jing et al. (2023), we use the sequences of the *apo* state as the primary sequence for model inference. **Twenty (20) conformations are sampled for each protein for evaluation.**
- **BPTI** (Bovine Pancreatic Trypsin Inhibitor) is a 58-amino-acid protein whose dynamics have been extensively studied through long-time MD simulations (Shaw et al., 2010). We use the structures

1620 of the five cluster centers identified in the MD study as the reference structures. This represents a
1621 five-state prediction task with Cluster 3 being the most challenging to sample (Wang et al., 2024c).
1622 One thousand (1,000) conformations are sampled for evaluation.

1623 [Model implementations]

- 1624 • EigenFold (Jing et al., 2023): The implementation is the same as in the folding task. See the
1625 section above for details.
- 1626 • MSA-subsampling (Del Alamo et al., 2022): We implemented MSA-subsampling using the
1627 `openfold v2.0.0` package by adjusting the two configuration parameters, `max_msa_clusters`
1628 and `max_extra_msa`, following Del Alamo et al. (2022). Specifically, we refer to `max_extra_msa`
1629 as the MSA depth and set `max_msa_clusters` to half that depth, while keeping other OpenFold
1630 settings at their default values. The original MSAs were obtained using the same ColabFold
1631 pipeline as in AlphaFold2.
- 1632 • Str2Str (Lu et al., 2024): We followed the official implementation of Str2Str and used OpenFold-
1633 predicted structure as the initial structures. Ensemble results were collected by uniformly sam-
1634 pling from t values. For BPTI, we used the author-recommended noising schedule with max-
1635 imum forward time of $T_{\max} = 0.15$ ($t = 0.10, 0.15$). For *apo-holo* and ATLAS datasets,
1636 we experimented with $T_{\max} = 0.1$ ($t = 0.06, 0.08, 0.10, 0.12, 0.14$) and $T_{\max} = 0.3$ ($t =$
1637 $0.06, 0.12, 0.18, 0.24, 0.30$) for both the SDE and ODE models.
- 1638 • AlphaFlow/ESMFlow (Jing et al., 2024): We used the official repository and released model
1639 weights for inference. The MSAs for AlphaFlow models were obtained through ColabFold’s
1640 pipeline. We included models pretrained on PDB (-PDB) and fine-tuned on MD datasets (-MD).
- 1641 • ConfDiff (Wang et al., 2024c): We followed the authors’ implementation and used the released
1642 weights for inference. In this benchmark, we used `recycle3` representations for both ConfDiff-
1643 Open and ConfDiff-ESM models, with comparison between classifier-free guidance models (-
1644 ClsFree), PDB base models (-PDB), and MD data fine-tuned models (-MD). The energy and force
1645 guidance models are dataset-specific and are only available for the BPTI dataset with ESMFold
1646 representations.

1647 [Extended comparison on protein conformation models]

1648 Recent works on protein conformational prediction have explored several strategies to extend folding
1649 models to generate multiple conformations. A common goal across these studies is to enhance
1650 sample diversity while ensuring that the generated conformations remain accurate and faithful to the
1651 protein, given the high-dimensional space of protein structure. Below, we briefly highlight the key
1652 differences among the studies and strategies evaluated in this benchmark:

- 1653 • **Perturbing the input of folding models.** While AlphaFold2 is designed to predict the single
1654 folded structure of a protein, several studies have proposed perturbing its MSA input to generate
1655 alternative structures (as a proxy to conformations) without re-training the model (Del Alamo
1656 et al., 2022; Wayment-Steele et al., 2024). In this benchmark, we assess MSA subsampling, a
1657 method that reduces the number of input MSAs (referred to as “depth”) by subsampling the full
1658 MSA, enabling the prediction of different structures due to the depletion of the input information.
1659 The depths of MSA controls the trade-offs between the sample diversity and how faithful the
1660 structure is to the protein.
- 1661 • **Perturbing folded structures.** Instead of perturbing the input to a folding model, Str2Str (Lu
1662 et al., 2024) perturbs the structure predicted from a folding model. It uses a structure-only dif-
1663 fusion model (i.e., a backbone design model) to perturb the input structure through a forward-
1664 backward diffusion process. The level of perturbation is controlled by the maximum diffusion
1665 time, T_{\max} . They also used ensembling by sampling at various diffusion times $t \leq T_{\max}$.
- 1666 • **Training generative models on large-scale structural data from experiments or simulations.**
1667 A more direct approach involves training sequence-conditioned generative models using diffusion
1668 or flow frameworks. EigenFold (Jing et al., 2023), AlphaFlow (Jing et al., 2024), and ConfD-
1669 iff (Wang et al., 2024c) follow similar approaches by fine-tuning a diffusion time t -dependent
1670 score or denoising model based on folding models, using structural data from PDB. Specifically,
1671 AlphaFlow finetunes all layers of AlphaFold2, while EigenFold and ConfDiff use pretrained rep-
1672 resentations from folding models and train a lightweight add-on module for score or denoising
1673

1674 prediction. Despite adopting a generative framework, models solely trained on PDB data are lim-
 1675 ited in predicting conformational distributions. To address this, AlphaFlow and ConfDiff further
 1676 fine-tuned their models on a recent MD dataset containing densely sampled conformations for
 1677 proteins (see Atlas in the Datasets section).

1678
 1679 • **Integrate physical priors in conformational training or sampling.** Due to limited availability
 1680 of large-scale protein conformation data from MD simulation, some models have explored inte-
 1681 grating structural and physical priors during training. ConfDiff (Wang et al., 2024c) introduced
 1682 two guidance techniques to improve conformational sampling: (1) classifier-free guidance, which
 1683 combines a sequence-conditioned conformation model with an unconditional (structure-only)
 1684 model to explore conformational space (ConfDiff-ClsFree), and (2) energy/force guidance, which
 1685 directs sampling toward regions with lower potential energy (ConfDiff-Energy/Force) through
 1686 auxiliary prediction modules for intermediate energy/force guidance. However, such physical
 1687 prediction modules are dataset-specific and requires training additional modules.

1688 [Extended Explanations and Discussion on Model Performance]

1689 The complete evaluation results for multiple-state prediction (BPTI and apo-holo) are shown in
 1690 Table 13 and Table 14.

1691 For **BPTI**, as discussed in the main text, certain conformation exploration techniques, such as MSA
 1692 subsampling and guidance used in ConfDiff, have shown their ability to sample diverse structures
 1693 while staying faithful to the protein. In contrast, structure-only approaches like Str2Str perform
 1694 poorly on this task, likely because these models do not ensure that the perturbed structure remains
 1695 faithful to the provided sequence. On the other hand, EigenFold shows limited diversity, as it was
 1696 trained solely on PDB structures and does not incorporate conformation exploration strategies. This
 1697 limits its effectiveness in sampling diverse samples. While AlphaFlow and ESMFlow demonstrate
 1698 competitive performance, fine-tuning on the MD dataset introduces trade-offs in quality, notably an
 1699 increased incidence of peptide bond breaking between residues.

1700 For **apo-holo**, strategies to improve sample diversity – such as reducing MSA depth, applying
 1701 structural perturbation, fine-tuning on MD conformation data, or using classifier-free guidance
 1702 – generally do not improve (and sometimes even reduce) the TMens score. Interestingly, we
 1703 found that the best-performing models are those that most closely resemble folding models (e.g.,
 1704 MSA-depth256, AlphaFlow-PDB). The included baseline *apo*, that always predicts the perfect *apo*
 1705 structures, confirmed that a higher TMens score can result from accurate prediction of one of the
 1706 states. These findings suggest that using better folding model provide a strong baseline performance
 1707 for conformational sampling but none of the current models show clear evidence of effectively
 1708 modeling conformational changes during complex biological processes, such as ligand binding.

1709 Table 13: Complete performance on the multiple-state prediction of BPTI. Accuracy metrics (RMS-
 1710 Dens, RMSD Cluster 3) are reported as the mean and standard deviations from 20 bootstrap samples
 1711 with replacement, at different sample sizes ($N = 10 \sim 1000$). Diversity and Quality scores are
 1712 evaluated based on 1,000 conformations for each model. The **best** performance is highlighted in
 1713 bold, and the second-best is underlined. “N/A” indicates not applicable due to model resolution.
 1714 RMSD is measured in Å.

| | RMSDens ↓ | | | RMSD Cluster 3 ↓ | | | Diversity | Quality | |
|-----------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|---------------|-------------|------------------|
| | N=10 | N=100 | N=1000 | N=10 | N=100 | N=1000 | Pairwise RMSD | CA clash% ↓ | PepBond break% ↓ |
| EigenFold | 1.56±0.02 | 1.50±0.01 | 1.46±0.00 | 2.54±0.03 | 2.48±0.01 | 2.46±0.01 | 0.85 | 1.4 | N/A |
| MSA-depth256 | 1.58±0.01 | 1.54±0.01 | 1.52±0.01 | 2.51±0.02 | 2.48±0.01 | 2.44±0.01 | 0.20 | 0.0 | 9.2 |
| MSA-depth64 | 1.60±0.01 | 1.55±0.02 | 1.51±0.01 | 2.46±0.03 | 2.41±0.04 | 2.34±0.03 | 0.55 | 0.0 | 7.9 |
| MSA-depth32 | 1.66±0.03 | 1.54±0.04 | 1.41±0.02 | 2.43±0.06 | 2.19±0.16 | 1.85±0.05 | 2.14 | 0.6 | 10.6 |
| Str2Str-ODE ($T_{\max} = 0.15$) | 2.40±0.12 | 2.20±0.05 | 2.09±0.01 | 3.00±0.20 | 2.73±0.12 | 2.58±0.05 | 1.86 | 0.0 | 13.9 |
| Str2Str-SDE ($T_{\max} = 0.15$) | 2.76±0.16 | 2.46±0.08 | 2.26±0.04 | 3.26±0.25 | 2.86±0.25 | 2.55±0.16 | 3.60 | 0.3 | 16.0 |
| AlphaFlow-PDB | 1.53±0.03 | 1.46±0.01 | 1.41±0.01 | 2.48±0.04 | 2.43±0.01 | 2.40±0.01 | 0.86 | 0.0 | 13.2 |
| AlphaFlow-MD | 1.71±0.08 | 1.51±0.03 | 1.43±0.01 | 2.46±0.09 | 2.32±0.06 | 2.25±0.01 | 1.26 | 0.0 | 26.2 |
| ESMFlow-PDB | 1.59±0.04 | 1.49±0.02 | 1.42±0.01 | 2.49±0.03 | 2.41±0.03 | 2.34±0.01 | 0.74 | 0.0 | 6.0 |
| ESMFlow-MD | 1.68±0.06 | 1.47±0.04 | 1.39±0.03 | 2.44±0.11 | 2.27±0.10 | 2.18±0.02 | 1.17 | 0.0 | 14.3 |
| ConfDiff-Open-MD | 1.64±0.05 | 1.50±0.02 | 1.43±0.02 | 2.50±0.05 | 2.38±0.04 | 2.31±0.02 | 1.37 | 0.2 | 4.6 |
| ConfDiff-Open-ClsFree | 1.66±0.06 | 1.50±0.04 | 1.37±0.02 | 2.56±0.07 | 2.39±0.17 | 2.02±0.10 | 1.77 | 0.5 | 5.5 |
| ConfDiff-ESM-MD | 1.62±0.04 | 1.47±0.02 | 1.40±0.01 | 2.45±0.09 | 2.32±0.05 | 2.25±0.02 | 1.42 | 0.1 | <u>5.0</u> |
| ConfDiff-ESM-ClsFree | 1.57±0.04 | 1.45±0.02 | 1.40±0.01 | 2.48±0.04 | 2.40±0.03 | 2.34±0.02 | 1.80 | 0.5 | <u>7.5</u> |
| ConfDiff-ESM-Energy | 1.61±0.03 | 1.46±0.02 | 1.42±0.01 | 2.51±0.05 | 2.44±0.03 | 2.40±0.01 | 1.22 | 0.1 | 7.5 |
| ConfDiff-ESM-Force | 1.58±0.04 | 1.43±0.03 | 1.36±0.01 | <u>2.44±0.06</u> | 2.35±0.05 | 2.24±0.06 | 1.76 | 0.1 | 8.9 |

Table 14: Performance on the conformation prediction task for the *apo-holo* dataset. *apolholo*-TM represents the maximum TM-score of the samples relative to the reference *apolholo* structure. Twenty conformations were sampled for each protein, and the results are reported as mean/median across 91 proteins. The **best** performance is highlighted in bold, and the second-best is underlined. “N/A” indicates not applicable due to model resolution.

| | Accuracy | | | Diversity | | Quality | |
|----------------------------------|---------------------------|----------------------------|------------------|-------------|-------------------------|------------------------------|--|
| | <i>apo</i> -TM \uparrow | <i>holo</i> -TM \uparrow | TMens \uparrow | Pairwise TM | CA clash % \downarrow | PepBond break % \downarrow | |
| <i>apo</i> model | 1.000 | 0.790 | 0.895 | N/A | N/A | N/A | |
| EigenFold | 0.831 | 0.864 | 0.847 | 0.907 | 3.6 | N/A | |
| MSA-depth256 | 0.845 | <u>0.889</u> | 0.867 | 0.978 | 0.2 | 4.6 | |
| MSA-depth64 | 0.844 | 0.883 | 0.863 | 0.950 | <u>0.2</u> | 5.7 | |
| MSA-depth32 | 0.824 | 0.857 | 0.841 | 0.864 | <u>0.2</u> | 8.9 | |
| Str2Str-ODE ($T_{\max} = 0.1$) | 0.762 | 0.778 | 0.770 | 0.954 | <u>0.2</u> | 14.0 | |
| Str2Str-ODE ($T_{\max} = 0.3$) | 0.766 | 0.781 | 0.774 | 0.872 | <u>0.2</u> | 14.7 | |
| Str2Str-SDE ($T_{\max} = 0.1$) | 0.682 | 0.693 | 0.688 | 0.760 | <u>0.2</u> | 22.6 | |
| Str2Str-SDE ($T_{\max} = 0.3$) | 0.680 | 0.689 | 0.684 | 0.639 | <u>0.2</u> | 21.1 | |
| AlphaFlow-PDB | <u>0.855</u> | 0.891 | 0.873 | 0.924 | 0.3 | 6.6 | |
| AlphaFlow-MD | 0.857 | 0.863 | 0.860 | 0.894 | 0.2 | 20.8 | |
| ESMFlow-PDB | 0.849 | 0.882 | 0.866 | 0.935 | 0.3 | 4.8 | |
| ESMFlow-MD | 0.851 | 0.864 | 0.858 | 0.897 | 0.1 | 10.9 | |
| ConfDiff-Open-PDB | 0.847 | 0.886 | 0.867 | 0.909 | 0.5 | 5.5 | |
| ConfDiff-Open-ClsFree | 0.838 | 0.879 | 0.859 | 0.870 | 0.8 | 5.8 | |
| ConfDiff-Open-MD | 0.839 | 0.874 | 0.857 | 0.863 | 0.4 | 6.8 | |
| ConfDiff-ESM-PDB | 0.845 | 0.873 | 0.859 | 0.890 | 0.5 | 4.1 | |
| ConfDiff-ESM-ClsFree | 0.837 | 0.864 | 0.850 | 0.846 | 0.7 | 4.6 | |
| ConfDiff-ESM-MD | 0.836 | 0.862 | 0.849 | 0.846 | 0.3 | 4.1 | |

B.2.3 DISTRIBUTION PREDICTION

[Task Definition] Distribution prediction challenges models to generate distributions that closely resemble a target distribution, such as the empirical distribution obtained from molecular dynamics (MD) simulations. Unlike previous two tasks, which focus on recovering specific conformations, this task requires models to demonstrate an understanding of “physics and energy” to accurately predict the conformational landscape at the distribution level. This approach further bridges the gap between protein conformation prediction models and MD-based methods for studying protein dynamics and thermodynamic properties.

[Evaluation Metrics] The **diversity** and **quality** evaluation are the same as in the previous task. We also included the average RMSF (root mean square fluctuation) as an additional metrics for atom-level diversities. To evaluate the **accuracy** of capturing the conformational distribution and dynamics of proteins, we extended the implementation⁶ from Jing et al. (2024), with a modification to explicitly align atom orders in `mdtraj` before comparing sample and reference structures. The accuracy are evaluated from three sub-categories:

- **Flexibility:** This metric assesses how accurately the generated samples reflect the protein’s flexibility at both the protein and atom levels. It is quantified by the Pearson correlation coefficient (r) between the diversity measures, such as Pairwise RMSD for protein or RMSF for atoms, of the model-generated samples and those of the reference MD samples.
- **Distributional accuracy:** This category evaluates the model’s accuracy on recovering the target distributions. Wasserstein-2 distances are used to measure the similarity between model-generated and reference distributions. RMWD is the root mean Wasserstein distance between the distributions of aligned coordinates, modeled as multivariate Gaussians. We also evaluate the W2 distance in the PCA projected subspace (PCA W2). Additionally, the cosine similarity between the first principal components from PCA analysis of model-generated and reference conformations serves as another indicator of how well the model captures the correct subspace.
- **Ensemble observables:** Another objective of conformational sampling is to identify certain functionally relevant behaviors (so called *observables*), such as transient residue-residue contacts observed in molecular dynamics. The accuracy on recovering such observables is assessed by comparing those derived from the model generated conformations to reference conformations, using metrics like Jaccard similarity or Spearman correlation.

[Datasets] We evaluate performance using the ATLAS dataset (Vander Meersch et al., 2024), a recent database of MD simulation results for diverse proteins. To avoid data leakage for models

⁶https://github.com/bjing2016/alphaflow/blob/master/scripts/analyze_ensembles.py

1782 trained on portions of the ATLAS dataset, we follow Jing et al. (2024) and benchmark on 82 proteins
1783 whose PDB entries were deposited after May 1, 2019 and are not part of the training or validation
1784 set. ATLAS is a recently published dataset containing triplicated 100 ns MD simulations for 1,390
1785 diverse single-chain proteins. In this work, we use a subset of 82 proteins whose PDB entries
1786 were deposited after May 1, 2019, following Jing et al. (2024). “Protein-only” trajectories were
1787 downloaded from the ATLAS database ⁷ for evaluation. We sample 250 conformations for each
1788 protein for evaluation.

1789 **[Model Implementations]** The models are implemented the same as in the multiple-state prediction
1790 task. See the previous Section B.2.2 for details.

1791 **[Extended Explanations and Discussion on Model Performance]**

1792 The complete evaluation results for distribution prediction (Atlas) are shown in Table 15. When
1793 comparing the effects of structure exploration strategies, classifier guidance used in ConfDiff stands
1794 out as the only approach that improves upon the base PDB model. In contrast, strategies such as
1795 MSA subsampling and structural perturbation in Str2Str negatively impact most accuracy metrics.
1796 However, as discussed in the main text, fine-tuning models on protein conformational data from
1797 MD simulations proved to be the most effective strategy, offering significant improvements over
1798 the base models. This contrasts with the challenges observed in multiple-state prediction tasks.
1799 The likely reason is that capturing conformational distributions requires detailed physical insights,
1800 which are difficult to extract solely from PDB structural data.

1801
1802
1803
1804
1805

1806 C DETAILED DISCUSSION OF KEY OBSERVATIONS

1807
1808 **Valid evaluation of protein foundation models requires accurate and comprehensive evaluation metrics.** The emergence of folding models like AlphaFold2 and ESMFold offers opportunities
1809 for precise assessment of quality, stability, and accuracy in protein generative tasks. However, **certain complex tasks may still lack sufficiently accurate evaluation methods.** For example, within
1810 the realm of antibody design, researchers have at times been misled by reconstruction metrics like
1811 Amino Acid Recovery (AAR) and Root Mean Square Deviation (RMSD) related to accuracy, result-
1812 ing in overly optimistic conclusions. In this study, we intend to tackle this challenge by proposing
1813 an evaluation strategy integrating reconstitution and physical rationality metrics. Also, we provide a
1814 **multifaceted evaluation strategy** to capture various facets of protein structure and function, foster-
1815 ing a more holistic understanding of the performance of foundation models. Furthermore, **metrics**
1816 **alone are insufficient.** In the development of generative models for protein, the primary objective
1817 is to accurately fit the distribution of the training data. Our evaluation adopts a more comprehensive
1818 strategy that includes measuring the same metrics for the training data (which encompasses native
1819 proteins, antibodies, and molecular dynamics conformations in various lengths). This provides a
1820 high-resolution gold reference for protein generative targets.

1821
1822 **No single model currently excels across all protein design objectives. The choice of model**
1823 **should be carefully aligned with the intended applications.** In the field of protein foundation
1824 models, two primary approaches have emerged: language models and geometric models. Each ap-
1825 proach has its strengths and limitations, which are reflected in the performance of ProteinBench.
1826 We found language models show good performance in capturing nature evolution distributions, evi-
1827 denced by their high accuracy in native sequence recovery (inverse-folding) and high quality in
1828 scaffolding evolution-conserved motifs. However, language models show limitations in robustness
1829 when designing sequences for de novo backbones, and in generating novel sequences for sequence-
1830 based protein design. In contrast, structure-based models exhibit greater robustness and tolerance
1831 for structural noises in de novo design task, and show greater potential for creating proteins with
1832 new folds or functions. These findings underscore the importance of carefully considering specific
1833 design objectives when researchers are selecting a model to use.

1834
1835

⁷<https://www.dsimb.inserm.fr/ATLAS/index.html>

1836 Table 15: Performance on distribution prediction for the ATLAS test set. A total of 250 conforma-
 1837 tions were sampled for each protein, and the median values across 82 proteins are reported. The
 1838 **best** performance is highlighted in bold, and the second-best is underlined. *These metrics require
 1839 all-atom or backbone predictions; therefore, EigenFold and Str2Str do not have sufficient resolution
 1840 for evaluation (indicated as “N/A”).

| | Diversity | | Flexibility: <i>Pearson</i> r on | | | Distributional accuracy | | | |
|----------------------------------|----------------------------|---------------------------------|------------------------------------|------------------------------------|-----------------------------|-------------------------------|------------------------|---------------------------|-----------------------------|
| | Pairwise RMSD | *RMSF | Pairwise RMSD \uparrow | *Global RMSF \uparrow | *Per target RMSF \uparrow | *RMWD \downarrow | MD PCA W2 \downarrow | Joint PCA W2 \downarrow | PC sim > 0.5 % \uparrow |
| MD iid | 2.76 | 1.63 | 0.96 | 0.97 | 0.99 | 0.67 | 0.73 | 0.71 | 93.9 |
| MD 2.5ns | 1.54 | 0.98 | 0.89 | 0.85 | 0.85 | 2.22 | 1.55 | 1.89 | 36.6 |
| EigenFold | 5.96 | N/A | -0.03 | N/A | N/A | N/A | 2.31 | 7.96 | 12.2 |
| MSA-depth256 | 0.83 | 0.53 | 0.25 | 0.34 | 0.59 | 3.60 | 1.79 | 2.91 | 29.3 |
| MSA-depth64 | 2.03 | 1.51 | 0.25 | 0.30 | 0.57 | 4.00 | 1.94 | 3.34 | 18.3 |
| MSA-depth32 | 5.70 | 7.96 | 0.08 | 0.17 | 0.53 | 6.09 | 2.56 | 5.70 | 17.1 |
| Str2Str-ODE ($T_{\max} = 0.1$) | 1.66 | N/A | 0.13 | N/A | N/A | N/A | 2.14 | 4.39 | 6.1 |
| Str2Str-ODE ($T_{\max} = 0.3$) | 3.15 | N/A | 0.13 | N/A | N/A | N/A | 2.19 | 4.80 | 9.8 |
| Str2Str-SDE ($T_{\max} = 0.1$) | 4.74 | N/A | 0.11 | N/A | N/A | N/A | 2.54 | 8.82 | 9.8 |
| Str2Str-SDE ($T_{\max} = 0.3$) | 7.54 | N/A | 0.01 | N/A | N/A | N/A | 3.24 | 12.28 | 7.3 |
| AlphaFlow-PDB | 2.58 | 1.20 | 0.27 | 0.46 | 0.81 | 2.97 | 1.61 | 2.61 | 37.8 |
| AlphaFlow-MD | 2.87 | 1.63 | <u>0.53</u> | <u>0.66</u> | 0.85 | 2.64 | 1.55 | <u>2.29</u> | <u>39.0</u> |
| ESMFlow-PDB | 2.99 | 1.68 | 0.14 | 0.27 | 0.71 | 4.15 | 1.87 | 3.61 | 28.0 |
| ESMFlow-MD | 3.33 | 2.13 | 0.19 | 0.30 | 0.76 | 3.61 | 1.66 | 3.25 | 25.6 |
| ConfDiff-Open-ClsFree | 3.68 | 2.12 | 0.39 | 0.54 | 0.83 | 2.91 | <u>1.54</u> | 2.46 | 46.3 |
| ConfDiff-Open-PDB | 2.89 | 1.43 | 0.38 | 0.51 | 0.82 | 2.96 | 1.59 | 2.46 | 34.1 |
| ConfDiff-Open-MD | 3.43 | 2.21 | 0.59 | 0.67 | 0.85 | 2.75 | 1.41 | 2.27 | 35.4 |
| ConfDiff-ESM-ClsFree | 4.04 | 2.84 | 0.31 | 0.43 | 0.82 | 3.78 | 1.73 | 3.07 | 37.8 |
| ConfDiff-ESM-PDB | 3.42 | 2.06 | 0.29 | 0.40 | 0.80 | 3.62 | 1.68 | 3.13 | 34.1 |
| ConfDiff-ESM-MD | 3.90 | 2.79 | 0.35 | 0.48 | 0.82 | 3.62 | 1.73 | 3.00 | 37.8 |
| | Ensemble observables | | | | Quality | | | | |
| | Weak contacts $J \uparrow$ | Transient contacts $J \uparrow$ | *Exposed residue $J \uparrow$ | *Exposed MI matrix $\rho \uparrow$ | CA clash % \downarrow | *PepBond break % \downarrow | | | |
| MD iid | 0.90 | 0.80 | 0.93 | 0.56 | 0.0 | 3.4 | | | |
| MD 2.5ns | 0.62 | 0.45 | 0.64 | 0.25 | 0.0 | 3.4 | | | |
| EigenFold | 0.36 | 0.19 | N/A | N/A | 5.6 | N/A | | | |
| MSA-depth256 | 0.30 | 0.29 | 0.36 | 0.06 | 0.0 | 5.5 | | | |
| MSA-depth64 | 0.38 | 0.28 | 0.40 | 0.16 | 0.0 | 7.6 | | | |
| MSA-depth32 | 0.40 | 0.24 | 0.40 | 0.19 | 0.1 | 11.2 | | | |
| Str2Str-ODE ($T_{\max} = 0.1$) | 0.42 | 0.18 | N/A | N/A | 0.0 | 12.1 | | | |
| Str2Str-ODE ($T_{\max} = 0.3$) | 0.42 | 0.17 | N/A | N/A | 0.0 | 13.2 | | | |
| Str2Str-SDE ($T_{\max} = 0.1$) | 0.40 | 0.13 | N/A | N/A | 0.1 | 21.9 | | | |
| Str2Str-SDE ($T_{\max} = 0.3$) | 0.36 | 0.13 | N/A | N/A | 0.2 | 20.2 | | | |
| AlphaFlow-PDB | 0.45 | 0.36 | 0.50 | 0.25 | 0.1 | 6.7 | | | |
| AlphaFlow-MD | <u>0.62</u> | 0.41 | 0.69 | 0.35 | 0.0 | 22.2 | | | |
| ESMFlow-PDB | <u>0.42</u> | 0.30 | 0.46 | 0.21 | 0.2 | 5.1 | | | |
| ESMFlow-MD | 0.55 | 0.34 | 0.57 | 0.29 | 0.1 | 10.9 | | | |
| ConfDiff-Open-ClsFree | 0.58 | 0.36 | 0.60 | 0.28 | 0.8 | 5.7 | | | |
| ConfDiff-Open-PDB | 0.50 | 0.36 | 0.54 | 0.25 | 0.5 | 5.6 | | | |
| ConfDiff-Open-MD | 0.63 | <u>0.39</u> | <u>0.65</u> | <u>0.33</u> | 0.5 | 6.5 | | | |
| ConfDiff-ESM-ClsFree | 0.57 | 0.34 | <u>0.59</u> | 0.23 | 0.9 | 4.3 | | | |
| ConfDiff-ESM-PDB | 0.50 | 0.33 | 0.50 | 0.24 | 0.5 | 4.0 | | | |
| ConfDiff-ESM-MD | 0.61 | 0.36 | 0.61 | 0.31 | 0.4 | <u>4.3</u> | | | |

1872 **While generative models extended from classic folding models have shown an ability to sample**
 1873 **protein conformations, challenges remain in both multiple-state prediction and distribution**
 1874 **prediction.** Protein conformation prediction is a new but crucial assessment of the multi-modal
 1875 capabilities and physical understanding of protein foundation models. While strategies proposed
 1876 in current models may benefit certain tasks, they often provide limited improvement in others. For
 1877 example, although fine-tuning models using the MD conformation dataset showed promising results
 1878 on the ATLAS benchmark, little to no improvement was observed in the multi-state prediction of
 1879 *apo-holo* conformations. Additionally, the common trade-off between diversity and quality in cur-
 1880 rent models underscores the importance of consistent evaluation across the dimensions of accuracy,
 1881 diversity, and quality in protein conformation prediction tasks.

1882
 1883
 1884
 1885
 1886
 1887
 1888
 1889